**Name of journal:** *World Journal of Gastroenterology*

**ESPS Manuscript NO: 7357**

**Columns: TOPIC HIGHLIGHT**

WJG 20th Anniversary Special Issues (9): Hepatitis B virus

**Hepatitis B virus coinfection in human immunodeficiency virus-infected patients: A review**

Sun HY *et al*. HBV and HIV coinfection

Hsin-Yun Sun, Wang-Huei Sheng, Mao-Song Tsai, Kuan-Yeh Lee, Sui-Yuan Chang, Chien-Ching Hung

**Hsin-Yun Sun, Wang-Huei Sheng, Chien-Ching Hung**, Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei 10617, Taiwan

**Mao-Song Tsai,** Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City 220, Taiwan

**Kuan-Yeh Lee,** Department of Internal Medicine, National Taiwan University Hospital Hsin-Chu Branch, Hsin-Chu 30059, Taiwan

**Sui-Yuan Chang,** Department of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University College of Medicine, Taipei 10617, Taiwan

**Sui-Yuan Chang,** Department of Laboratory Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei 10617, Taiwan

**Chien-Ching Hung,** Department of Medical Research, China Medical University Hospital, China Medical University, Taichung 40447, Taiwan

**Author contributions:** Sun HY, Sheng WH, Tsai MS, Lee KY, Chang SY, and Hung CC performed the literature search and review, and wrote the paper; Chang SY and Hung CC edited and revised the manuscript.

**Supported by** Centers for Disease Control, Taiwan, grant number: DOH 102-DC-1401

**Correspondence to: Chien-Ching Hung, MD, PhD, Clinical Associate Professor,** Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, 7 Chung-Shan South Road, Taipei 10617, Taiwan. hcc0401@ntu.edu.tw

**Telephone:** +886-2-23123456-67552 **Fax:** +886-2-23707772

**Received:** November 14, 2013 **Revised:** December 24, 2013

**Accepted:** April 27, 2014

**Published online:**

**Abstract**

Hepatitis B virus (HBV) infection is a leading cause of chronic hepatitis, cirrhosis of the liver, and hepatocellular carcinoma worldwide. Due to the shared modes of transmission, coinfection with HBV and human immunodeficiency virus (HIV) is not uncommon. It is estimated that 10% of HIV-infected patients worldwide are coinfected with HBV. In areas where HBV vaccination program is implemented, the HBV seroprevalence has declined significantly. In HIV/HBV-coinfected patients, HBV coinfection accelerates immunologic and clinical progression of HIV infection and increases risk for hepatotoxicity when combination antiretroviral therapy (cART) is initiated, while HIV infection increases the risk of hepatitis events, cirrhosis, and end-stage liver disease related to chronic HBV infection. With the advances in antiviral therapy, concurrent, successful long-term suppression of HIV and HBV replication can be achieved in the cART era. To reduce the disease burden of HBV infection among HIV-infected patients, adoption of safe sex practices, avoidance of sharing needles and diluent, HBV vaccination and use of cART containing tenofovirdisoproxil fumarate plus emtricitabine or lamivudine are the most effective approaches. However, due to HIV-related immunosuppression, using increased doses of HBV vaccine and novel approaches to HBV vaccination are needed to improve the immunogenicity of HBV vaccine among HIV-infected patients.

© 2014 Baishideng Publishing Group Co., Limited. All rights reserved.

**Key words:** Viral hepatitis; Seroepidemiology; Sexually transmitted diseases; Nucleoside reverse-transcriptase inhibitor; Vaccination

**Core tip:** We provide an updated review of hepatitis B virus (HBV) coinfection among human immunodeficiency virus (HIV)-infected patients, focusing on the epidemiology, management and prevention for HBV infection. The mutually detrimental interactions between HBV and HIV are discussed. Three updated treatment guidelines for management of patients with HIV/HBV coinfection are summarized. We also review the published data of effectiveness or efficacy of HBV vaccination studies, with emphasis on the different approaches to improvement of the serologic responses to conventional HBV vaccine among HIV-infected patients.

Sun HY, Sheng WH, Tsai MS, Lee KY, Chang SY, Hung CC. Hepatitis B virus coinfection in human immunodeficiency virus-infected patients: A review.

*World J Gastroenterol* 2014; In press

**INTRODUCTION**

Hepatitis B virus (HBV) infection is a leading cause of chronic hepatitis, cirrhosis of the liver, and hepatocellular carcinoma (HCC) worldwide[[1](#_ENREF_1)]. Due to the shared modes of transmission, coinfection with HBV and human immunodeficiency virus (HIV) is not uncommon. It is estimated by the Joint United Nations Program on HIV/AIDS that 10% of 33 million HIV-infected patients has concurrent chronic HBV infection[[2](#_ENREF_2)]. The prevalence or incidence of HBV infection among HIV-infected patients may vary widely with risks for HIV and HBV transmission, implementation of HBV vaccination programs, and the geographic regions with different endemicities of HBV infection in the general population[[2](#_ENREF_2)]. HBV and HIV have mutually detrimental impact in that HIV infection accelerates HBV-related liver damage, leading to earlier cirrhosis and end-stage liver disease[[3](#_ENREF_3),[4](#_ENREF_4)], and the presence of HBV infection complicates the management of HIV infection, impairs CD4 recovery, accelerates immunologic progression, and increases the morbidity and mortality of HIV-infected patients[[4-8](#_ENREF_4)]. In this article we review the epidemiology, interactions between HIV and HBV, and management and prevention of HBV infection in HIV-infected patients in the era of combination antiretroviral therapy (cART) that often contains 1 or 2 nucleos(*t*)ide reverse-transcriptase inhibitors (NRTIs) that are active against HBV as well as HIV.

**Epidemiology of hepatitis B virus coinfection in HIV-infected patients**

***Epidemiology of hepatitis B virus in HIV-infected populations***

According to the World Health Organization[9], the world can be divided into 3 areas based on the levels of endemicity of HBV infection that are defined by the prevalence of chronic HBV infection: low endemicity, < 2%; intermediate endemicity, 2%-8%; and high endemicity, > 8%. In areas of high endemicity of chronic HBV infection, the transmission of HBV mainly occurs through perinatal transmission (predominantly in east and southeast Asia) or in young children through close household contact or through medical or traditional scarification procedures (predominantly in Africa)[[2](#_ENREF_2),[9](#_ENREF_9)]. Given the shared transmission routes of HIV and HBV, coinfection with HBV and HIV is common. Approximately 10% of HIV-infected population in Asia and Africa has concurrent chronic HBV infection with coinfection more common in areas of high prevalence for both viruses[[2](#_ENREF_2),[10](#_ENREF_10)]. The rate can be as high as 25% in countries where the viruses are highly endemic[[10](#_ENREF_10)]. In areas where HBV is less endemic (North America, Europe, and Australia), HBV and HIV are most often acquired during the adolescence or adulthood through sexual transmission or injection drug use[[10](#_ENREF_10)]. In western Europe and the United States, the overall prevalence of chronic HBV infection among HIV-infected persons is estimated 6%-14%[[3](#_ENREF_3),[4](#_ENREF_4),[11-13](#_ENREF_11)], including 4%-6% of HIV-infected heterosexuals[[3](#_ENREF_3),[12](#_ENREF_12)], 9%-17% of HIV-infected men who have sex with men (MSM)[[3](#_ENREF_3),[11](#_ENREF_11),[12](#_ENREF_12)], and 7%-10% of injecting drug users[[3](#_ENREF_3),[4](#_ENREF_4),[11](#_ENREF_11),[12](#_ENREF_12)]. Previous studies have shown that seropositivity for syphilis and HIV infection, the number of lifetime sexual partners, and receptive anal intercourse are associated with increased risk of HBV infection in MSM[[14-16](#_ENREF_14)].

***Seroprevalence of hepatitis B virus before and after implementation of vaccination***

In a recent review of global epidemiology of HBV infection[[17](#_ENREF_17)], the prevalence of HBV infection has been shown to be decreasing, particularly evident in central sub-Saharan Africa, tropical and central Latin America, southeast Asia and central Europe. Expanded programs of immunization against HBV have been proposed to significantly contribute to such an observation[[17](#_ENREF_17)]. In areas that implemented universal neonatal HBV vaccination program such as Taiwan and Alaska, the incidence of acute HBV infection[[18](#_ENREF_18),[19](#_ENREF_19)], prevalence of chronic HBV infection[[19](#_ENREF_19),[20](#_ENREF_20)], and incidence of HCC in children have significantly declined[[19](#_ENREF_19),[21](#_ENREF_21)], so have the mortality of chronic liver disease as well as HCC in persons aged 5-29 years[[22](#_ENREF_22)].

Recent studies that evaluated the long-term impact of universal neonatal HBV vaccination on the HBV seroprevalence among HIV-infected populations and persons at high risk for HIV transmission in Taiwan also demonstrated decreasing trends of chronic HBV infection in those persons born after implementation of neonatal HBV vaccination and catch-up vaccination programs (Figure 1)[[23](#_ENREF_23),[24](#_ENREF_24)]. The prevalence of hepatitis B surface antigen (HBsAg) positivity of HIV-infected patients born after July 1984, when nationwide HBV vaccination program in Taiwan was initially implemented to vaccinate newborns of HBsAg-positive mothers, have declined to 3.3% compared to 20.3% in those born before July 1984 (*P* < 0.05)[[23](#_ENREF_23)]. Furthermore, the prevalence of HBsAg positivity was similar between HIV-infected MSM and HIV-uninfected MSM (3.7% *vs* 2.4%) who were born in the era of universal HBV vaccination (in or after 1986) despite the fact that HIV-infected MSM were more likely to have syphilis (21.2% *vs* 2.8%) and had a higher prevalence of HBV core antibody (anti-HBc) positivity (26.3% *vs* 19.6%), while HIV-infected MSM born in 1984-1985 had a significantly higher prevalence of HBsAg positivity than HIV-infected MSM born in or after 1986 (7.8% *vs* 3.7%)[[24](#_ENREF_24)]. Additionally, syphilis and positive anti-HCV were significantly associated with HBsAg positivity in HIV-infected patient born in the era of universal HBV vaccination.

***Genotype distribution of HBV and its impact***

Based on the extent of genetic diversity in HBV sequences, HBV can be divided into 10 genotypes (A to J) and several subtypes[[25](#_ENREF_25),[26](#_ENREF_26)]. Genotypes A to D are more prevalent, with genotype A in sub-Saharan Africa, Northern Europe, and West Africa; genotypes B and C in Asia; and genotype D in Africa, eastern Europe, the Mediterranean region, and India. Other HBV genotypes are less prevalent with genotype E in West Africa; genotype F in Central and South America; genotype G in France, Germany, and the US; and genotype H in Central America. Unlike other genotypes, the 2 newly identified genotypes, I and J, have yet to establish characteristic geographic and ethnic distribution. Genotype I is known as a recombinant of genotypes A, C, and G, and was found in Vietnam and Laos[[27](#_ENREF_27)]. Genotype J was first identified in Ryukyu Island, Japan[[28](#_ENREF_28)].

Many retrospective and prospective studies have been conducted to determine the impact of HBV genotypes on disease outcomes among the general population. Although some controversial results were observed likely due to the transmission route and age when HBV infection occurs, which are closely correlated with seroprevalence of HBV in the geographic areas studied, several studies suggested that patients infected with genotypes C and D had lower rates of seroconversion than patients infected with genotypes A and B, which is likely correlated with the relatively delayed onset of spontaneous HBV envelope antigen (HBeAg) seroconversion and HBsAg seroclearance[[29-31](#_ENREF_29)]; infection with genotype C was associated with an increased risk of HCC than with genotype B in retrospective, prospective, and case-control studies[[32-36](#_ENREF_32)]; and patients infected with genotype C tended to have higher HBV viral load and higher frequency of basal core promoter A1762T/G1764A mutation than those with genotype B[[34](#_ENREF_34),[35](#_ENREF_35),[37](#_ENREF_37)]. In addition, although HBV genotyping before antiviral therapy is not recommended by current guidelines[[38](#_ENREF_38)], the impact of HBV genotypes on clinical responses to interferon (IFN) have been described. First, in HBeAg-positive patients receiving standard IFN-α, the sustained virologic response rate was higher in patients infected with genotypes A and B than those with genotypes C and D[[39-41](#_ENREF_39)]. Even among HBeAg-negative patients treated with IFN-α, HBsAg clearance was significantly higher in patients with genotype A (20%) than those with genotypes B (6%), C (9%), and D (6%)[[42](#_ENREF_42)]. While Chien et al[[43](#_ENREF_43)] first reported that the sustained response rate to lamivudine (LAM) was much higher in patients with genotype B than those with genotype C, subsequent studies demonstrated similar therapeutic responses or risk of emergence of LAM resistance among patients infected with different HBV genotypes[[44-46](#_ENREF_44)]. No statistically significant difference was observed in response to adefovir dipivoxil (ADV)[[47](#_ENREF_47)] and telbivudine (LdT)[[48](#_ENREF_48)], either.

In HIV/HBV-coinfected patients, HBV genotypes A is the most prevalent in Western countries[[49](#_ENREF_49)], although the distribution of HBV genotypes might also vary according to the risk factors, geographic origin, and coinfection with other hepatitis viruses[[50](#_ENREF_50),[51](#_ENREF_51)]. The impact of HBV genotypes on the course of HBV infection observed included more advanced fibrosis in patients infected with non-A genotypes[[49](#_ENREF_49)], especially with genotype G[[52](#_ENREF_52)], although a recent study with more than 5 years of follow-up demonstrated that infection with HBV genotype G was not significantly associated with severe liver disease and had no impact on fibrosis progression[[53](#_ENREF_53)]. In another study in HIV/HBV-coinfected patients receiving long-term LAM-containing ART by Sheng *et al*[[54](#_ENREF_54)], patients coinfected with genotype B were more likely to experience acute exacerbations of hepatitis, HBeAg seroconversion, LAM resistance, and liver disease-related death than those coinfected with genotype C.

**Interactions between HBV and HIV in the era of combination antiretroviral therapy**

***Impact of HBV coinfection on HIV infection***

It is suggested that persistent state of immune activation in patients with chronic HBV infection could up-regulate HIV replication[[55](#_ENREF_55)], and an *in vitro* study showed HBV X protein could induce ongoing HIV replication and long-term repeated transcription of HIV by synergizing with kappa B-like enhancer and T-cell activation signals[[56](#_ENREF_56),[57](#_ENREF_57)]. Early prospective cohort studies of HIV/HBV-coinfected patients revealed a 3.6 to 6.8-fold relative risk of progression to AIDS than those without[[58](#_ENREF_58),[59](#_ENREF_59)]. However, other reports failed to confirm the results[[3](#_ENREF_3),[60](#_ENREF_60)]. To minimize the inﬂuence of duration of HIV infection, a prospective observational cohort of adult patients with primary HIV infection (seroconversion window ≤ 6 mo)[[7](#_ENREF_7)] have shown that HBV coinfection (adjusted hazards ratio, 3.46; 95%CI: 1.16-10.32) was an independent predictors of immunologic progression that was deﬁned as the occurrence of a CD4 cell count < 350 cells/μL 3 mo or greater after diagnosis of primary HIV infection[[7](#_ENREF_7)]. Chun *et al*[[6](#_ENREF_6)] examined the interactions of HBV and HIV using the composite endpoint of AIDS-deﬁning illnesses and death among HIV-infected individuals who had seroconversion window of ≤ 3 years in a large cohort, which revealed that the hazards ratio for an AIDS or death event was almost double (adjusted hazards ratio, 1.80; 95%CI: 1.20-2.69) for those with HBV coinfection. The adverse impact of HBV on HIV is also recently demonstrated by the Swiss HIV Cohort Study[[8](#_ENREF_8)], in which patients who tested positive for HBsAg had significantly impaired CD4 recovery during the first 3 years of cART despite similar virologic effectiveness of antiretroviral therapy compared to patients without HBV infection [504 cells/μL (95%CI: 496-511) *vs* 449 cells/μL (95%CI: 428-469)].

***Impact of HIV infection on HBV infection***

Compared to HIV-uninfected subjects, patients with HIV infection have a higher risk of chronicity after acute HBV infection[[61](#_ENREF_61)]. A higher proportion of chronic HBs antigenemia has been found in HIV-infected patients because HIV destroys CD4 cells that compromises host immunity against HBV[[62](#_ENREF_62)]. A previous study on pregnant women with chronic HBV infection in Zambia showed that those with HIV coinfection had a 3-fold higher HBeAg-positive rate than HIV-uninfected pregnant women (25% *vs* 8.5%, *P* < 0.05)[[63](#_ENREF_63)]. Another similar study showed that HBV DNA was detected in 26.7% of pregnant women with HIV/HBV coinfection *vs* 9.4% of those with HBV infection alone (*P*=0.06)[[64](#_ENREF_64)]. Clinical observational studies have demonstrated that HIV/HBV-coinfected patients may have faster progression of hepatic fibrosis and a higher risk of cirrhosis, end-stage liver disease, and HCC than HBV-monoinfected patients[[4](#_ENREF_4),[65](#_ENREF_65)]. Similarly, compared with HIV-monoinfected patients, patients with HIV/HBV coinfection, especially HBV genotype B, had a higher risk of acute hepatitis, hepatic decompensation, and liver-related mortality[[4](#_ENREF_4),[54](#_ENREF_54),[66](#_ENREF_66)]. Superinfection or coinfection with hepatitis D virus may further exacerbate the complications in patients with HIV/HBV coinfection, which has recently been observed to increase in incidence in an area used to be hyperendemic for HBV infection in the general population[[67](#_ENREF_67),[68](#_ENREF_68)].

**Management of HBV coinfection in HIV-infected patients**

***Interferon and nucleos(t)ide reverse-transcriptase inhibitors***

The goal of antiviral therapy for HBV is to suppress HBV DNA replication, reduce necroinflammatory activity, and prevent progression to cirrhosis and HCC. At present, seven therapeutic agents, including IFN, pegylated-interferon (peg-IFN), LAM, emtricitabine (FTC), ADV, entecavir (ETV), LdT and tenofovir disoproxil fumarate (TDF) are approved by the US Food and Drug Administration (FDA) for treatment of chronic HBV infection [[69](#_ENREF_69)]. The characteristics of anti-HBV therapeutic agents are shown in Table 1[[70-81](#_ENREF_70)]. LAM, FTC and TDF have both anti-HBV and anti-HIV activities. According to current treatment guidelines for HIV-infected adult patients, when patients meet the criteria to start cART, 2 agents active against HBV should be included and the most commonly chosen option is TDF in combination with either FTC or LAM[[69](#_ENREF_69),[82](#_ENREF_82)]. If TDF is not available or not well tolerated, other options include either ADV or ETV in combination with either FTC or LAM are recommended (Table 2)[[82-84](#_ENREF_82)]. CART regimens containing LAM as the only agent with anti-HBV activity should be avoided because of high risk of emergence of HBV with LAM resistance during therapy[[85-90](#_ENREF_85)].

***IFN***

Peg-IFN is superior to conventional IFN in the treatment of chronic HBV infection because of its long-acting characteristics and weekly administration[[91](#_ENREF_91)]. The response rate of HBeAg seroconversion and suppression HBV replication to peg-IFN with or without LAM among HBV-monoinfected patients ranges from 24% to 32%[[91](#_ENREF_91),[92](#_ENREF_92)], compared with 0% to 20% among HBV/HIV-coinfected patients[[71](#_ENREF_71)]. Nevertheless, IFN should be avoided in patients with low CD4 counts because of significant lymphocytopenia related to IFN[[93](#_ENREF_93)]. As IFN has potential anti-HIV effects[[94](#_ENREF_94)] without resulting in emergence of IFN-resistant HIV[[93](#_ENREF_93)], IFN can be used in those who may need anti-HBV therapy but not anti-HIV therapy (*e.g.*, CD4 count ≥ 500 cells/μL). However, IFN is contraindicated in patients with decompensated liver disease because of concerns about hepatic failure and deaths during IFN treatment[[95](#_ENREF_95)].

***Lamivudine and emtricitabine***

LAM has activity against both HIV and HBV at the daily dose of 300 mg and 100 mg, respectively. This agent is well tolerated with few adverse effects[[96](#_ENREF_96)]. The rates of HBeAg seroconversion and HBV viral suppression (HBV DNA < 400 copies/mL) among HBV/HIV-coinfected patients receiving LAM 300 mg daily for 1 year ranged from 22% to 35% and 40% to 84%, respectively[[85-88](#_ENREF_85)]. However, the genetic barrier to LAM resistance is low and LAM resistance rates may be as high as 50% after 2 years and 90% after 4 years of LAM therapy in HIV/HBV-coinfected patients[[85-90](#_ENREF_85)].

FTC is a cytosine analogue that is structurally similar to LAM, and the daily dose for both HBV and HIV is 200 mg. The resistance profile and efficacy of FTC against HIV and HBV are also similar to LAM[[97](#_ENREF_97),[98](#_ENREF_98)]. After 2 years of treatment with FTC, 53% of HBV-monoinfected patients had undetectable serum HBV DNA (< 4700 copies/mL), 33% seroconverted to anti-HBe, and 85% had normal alanine aminotransferase (ALT) levels. The rate of mutations in YMDD motif was 18% at 2 years of FTC treatment[[99](#_ENREF_99)]. In a small cohort of 16 HBV/HIV-coinfected patients treated with TDF and FTC for 48 wk, 94% patients had undetectable serum HBV DNA and 14% of them seroconverted to anti-HBe[[100](#_ENREF_100)].

LAM may promote the selection of resistant mutations in the HBV DNA polymerase gene at the YMDD motif, rtM204V/I, which predisposes to cross-resistance to FTC and LdT[[101](#_ENREF_101)]. Furthermore, the common LAM-resistant mutations, rtL180M and rtM204V, are 2 of the 3 major mutations required for the development of ETV resistance. In addition, rtA181T/V mutation confers cross resistance to ADV[[102](#_ENREF_102)]. Therefore, combination of LAM with other anti-HBV agents without cross resistance as part of antiretroviral therapy is the most effective approach to prevention against emergence of LAM-resistant HBV strains among HIV/HBV-coinfected patients.

***Adefovir dipivoxil***

ADV had sustained antiviral activity against LAM-resistant HBV strains in 29 HIV/HBV-coinfected patients throughout 144 wk of treatment, with 25% achieving undetectable HBV DNA and 9% HBeAg seroconversion[[103](#_ENREF_103)]. In a prospective randomized controlled study of 52 HBV/HIV-coinfected patients, the anti-HBV activity of ADV were comparable to TDF (average change in serum HBV DNA from baseline to week 48, -4.44 log copies/mL for TDF and -3.21 log10 copies/mL for ADV)[[78](#_ENREF_78)]. The incidence of HBV resistant to ADV is less frequent than that to LAM[[104](#_ENREF_104),[105](#_ENREF_105)]. Mutations at rtN236T and rtA181V, which confer resistance to ADV, occurred in 29% of the patients receiving 5 years of ADV treatment[[105](#_ENREF_105)]. These mutations are potentially cross-resistant to TDF, and rtA181V is partially cross-resistant to LAM[[102](#_ENREF_102)]. The rate of ADV resistance is markedly reduced when ADV is added to LAM rather than used as sequential monotherapy in patients with LAM-resistant HBV infection[[106](#_ENREF_106),[107](#_ENREF_107)]. In addition, no genotypic resistance of HIV to ADV was found after 3 years of therapy[[103](#_ENREF_103)].

***Tenofovir disoproxil fumarate***

TDF is a potent agent and effective against LAM-resistant HBV[[108](#_ENREF_108)] and ADV-resistant HBV[[109](#_ENREF_109)]. In a study that included 110 HIV/HBV-coinfected patients with 57% being HBeAg-positive at baseline, TDF-containing cART led to high rates of HBeAg seroconversion after 5 years of treatment: 21% for LAM group, 50% TDF group and in 57% TDF plus FTC group[[110](#_ENREF_110)]. During a median observation period of 83 mo, 91% achieved suppression of HBV replication[[110](#_ENREF_110)]. In a meta-analysis of available data from 23 studies that included 550 HBV/HIV-coinfected patients treated with TDF[[111](#_ENREF_111)], the overall proportion achieving suppression of HBV replication was 57.4%, 79.0% and 85.6% at 1, 2 and 3 years, respectively, and prior or concomitant 3TC or FTC did not impact the virologic response of HBV infection to TDF; furthermore, virologic rebound on TDF treatment was rare. Those findings of dual anti-HBV and anti-HIV activity and high genetic barrier to resistance have made TDF an attractive option for the treatment of both viruses in patients with HIV/HBV coinfection. However, TDF may cause renal impairment (1%-3%), which includes Fanconi’s syndrome, tubular dysfunction, increases in serum creatinine, and, in rare cases, acute renal failure. Therefore, regular monitoring of renal function is advised in patients receiving TDF-containing regimens is advised[[112](#_ENREF_112)].

***Entecavir***

ETV is a guanosine analogue that is highly active against wild-type HBV at a daily dose of 0.5 mg and LAM-resistant HBV at 1 mg. It has been demonstrated that ETV reduced HBV DNA by 4.20 log10 copies/mL in HIV/HBV-coinfected patients with HBV resistant to LAM at 48 wk of therapy[[113](#_ENREF_113)]. ETV has been found to be associated with a 1-log10 reduction of plasma HIV RNA load and mutation in HIV polymerase (rtM184V) that confers resistance to both LAM and FTC[[114](#_ENREF_114)]. ETV resistance results from 3 major mutations, rtL180M, rtM204V and either rtT184G/S, rtS202I or rtM250V. The first 2 mutations also confers resistance to LAM[[115](#_ENREF_115)]. Therefore, ETV is not recommended as monotherapy in HIV/HBV-coinfected patients.

***Telbivudine***

Data on the antiviral effect of LdT against HBV in HIV/HBV-coinfected patients are sparse. In HBV-monoinfected patients, LdT decreased HBV DNA levels by 6.45 log10 copies/mL in HBeAg-positive and 5.23 log10 copies/mL in HBeAg-negative patients[[116](#_ENREF_116),[117](#_ENREF_117)]. LdT has greater anti-HBV efficacy than LAM or ADV, and selects for resistance mutations at an intermediate rate. Resistant mutations were selected in 11% of HBeAg-negative and 25% of HBeAg-positive patients after 2 years of treatment with LdT[[116](#_ENREF_116),[117](#_ENREF_117)]. In an *in vitro* and human study, LdT was not shown to exert antiviral activity against HIV-1[[77](#_ENREF_77)], while a transient reduction of HIV-1 RNA between 2 and 3 log10 copies/ml after 24 wk of telbivudine therapy for in 2 out of 3 patients without showing genotypic resistance mutations to antiretrovirals[[81](#_ENREF_81)].

***Impact on progression to end-stage liver diseases or regression of cirrhosis and reduced risk of recurrent HCC***

Serum HBV DNA level is a marker of viral replication and efficacy of antiviral treatment in individuals with chronic HBV infection. Maintaining suppression of HBV replication using anti-HBV therapy may reduce the progression of liver fibrosis, reverse advanced fibrosis, reduce the development of cirrhosis, and prevent hepatic decompensation and HCC in patients with advanced fibrosis or cirrhosis. In a prospective cohort study of 3653 HBsAg-positive participants (aged 30-65 years) in Taiwan[[118](#_ENREF_118)], the incidence of HCC increased with increasing serum HBV DNA levels at study entry in a dose-response relationship, from 108 per 100000 person-years for patients with an HBV DNA level of < 300 copies/mL to 1152 per 100000 person-years for those with an HBV DNA level of 1 million copies/mL or greater; the corresponding cumulative incidence rates of HCC were 1.3% and 14.9%, respectively. A high serum HBV DNA level (≥ 10000 copies/mL) is a significant risk predictor of HCC independent of HBeAg, serum alanine aminotransferase level, and cirrhosis of the liver[[118](#_ENREF_118)].

In a systemic review of 21 studies conducted among 3881 anti-HBV NRTI-treated (for at least 24 mo or more) and 534 untreated patients, HCC developed less frequently in anti-HBV NRTI-treated patients (2.8% *vs* 6.4%, *P*=0.003) during a 46 mo (range, 32-108 mo) observation period[[119](#_ENREF_119)]; furthermore, HCC developed significantly less frequently in patients remaining in virologic remission than in those with virologic breakthrough or no response (2.3% *vs* 7.5%, *P* < 0.001)[[119](#_ENREF_119)]. In a recent report conducted in HIV-uninfected population, long-term ETV treatment reduced the incidence of HCC in HBV-infected patients and the treatment effect was greater in patients at higher risk of HCC[[120](#_ENREF_120)]. These findings provide supportive evidence to the well-known association between the biologic gradients of HBV DNA levels and risk of HCC[[118](#_ENREF_118)].

***Management of lamivudine resistance***

If LAM-resistant HBV is present, LAM can be continued for the management of HIV because LAM-resistant HIV has reduced viral fitness *in vitro* and slower progression *in vivo*. TDF, ADV and ETV are active against LAM-resistant HBV[[78](#_ENREF_78),[103](#_ENREF_103),[108](#_ENREF_108),[109](#_ENREF_109),[113](#_ENREF_113),[121](#_ENREF_121)]. A previous study comparing the efficacy of TDF and LAM combination therapy *vs* TDF after LAM failure for the treatment of HBV in HIV/HBV-coinfected patients revealed no statistically significant difference in terms of HBeAg loss or HBV suppression[[122](#_ENREF_122)]. ETV is less preferred because LAM resistance predisposes to ETV resistance[[115](#_ENREF_115)]. However, a small cohort of 13 patients with positive HBeAg and detectable HBV DNA who had received > 6 mo of TDF/FTC therapy, add-on ETV to TDF/FTC-experienced patients achieved undetectable HBV DNA load in 4 (30%) and normal ALT levels in 8 (62%)[[79](#_ENREF_79)].

During anti-HBV treatment, monitoring of liver functions (alanine aminotransferase, aspartate aminotransferase, and total bilirubin) is advised every 3 to 6 mo and serum HBV DNA levels every 6 to 12 mo[[83](#_ENREF_83)]. The presence of detectable serum HBV DNA with the use of sensitive assays after 24 wk of therapy suggests a suboptimal response or treatment failure, and add-on therapy with agents without cross resistance should be considered at this stage[[102](#_ENREF_102)].

***Management of end-stage liver disease***

The advances in therapy for HIV infection have prolonged the life expectancy in HIV-infected patients receiving cART[[123](#_ENREF_123)], which has led to a greater need for treating HBV-related chronic complications. The 2 major adverse outcomes in patients with chronic HBV infection are cirrhosis and HCC, both of which can lead to liver-related death[[124](#_ENREF_124)]. A low CD4 cell count in HIV/HBV-coinfected patients has been associated with increased risk of cirrhosis and HCC[[10](#_ENREF_10),[125](#_ENREF_125),[126](#_ENREF_126)]. Overall, less treatable cases and lower survival rates have been described in HIV-infected patients following the diagnosis of HCC[[4](#_ENREF_4)]. New treatment strategies are available for advanced HCC but data are limited for HIV/HBV-coinfected patients. Case reports suggest some benefit from sorafenib treatment in HIV/HBV-infected patients with newly diagnosed HCC[[127-130](#_ENREF_127)]. For most patients with end-stage liver disease, orthotopic liver transplantation remains the only therapeutic option. Accumulated experience in North America and Europe indicated that the patient and graft survival rates in selected HIV-infected recipients of liver transplants were almost similar to those of HIV-uninfected recipients[[131](#_ENREF_131),[132](#_ENREF_132)]. Therefore, HIV infection by itself is not a contraindication to liver transplantation. Together with screening of patients at risk and an early diagnosis, aggressive treatment of HCC, including treatment of relapses and maintenance of HIV and HBV suppression, are the best management strategies for HCC in people living with HIV. All patients should receive anti-HBV NRTIs, and hepatitis B immune globulin indefinitely post-transplantation with a decrease in dose frequency after 12 mo[[131](#_ENREF_131)]. It is recommended that patients with liver disease should start referral and workup for liver transplantation if they become symptomatic with liver disease[[133](#_ENREF_133)], which includes the development of hepatic encephalopathy, ascites, variceal bleeding, or liver dysfunction with albumin < 3 g/dL and prolongation of prothrombin time by > 5 s[[133](#_ENREF_133)].

**Prevention of HBV infection among HIV-infected patients**

Although the modes of transmission of HBV are the same with those of HIV, HBV is transmitted more efficiently than HIV[[134](#_ENREF_134),[135](#_ENREF_135)]. Other than adoption of safe sex practices and avoidance of sharing needles and diluent, HBV vaccination remains the most effective approach to prevention against HBV infection and its chronic consequences. According to the HIV treatment guidelines by US Department of Health and Human Services[[82](#_ENREF_82)], pre-vaccination screening should include HBsAg, anti-HBsAg antibody (anti-HBs), and anti-HBc. Serological markers may be time-dependent variables in HIV-infected patients, which is associated with host immunity and viral activities; and, therefore, periodic measurements are recommended[[5](#_ENREF_5)]. The presence of anti-HBs at levels of > 10 international units/L (IU/L) is consistent with seroprotection and at levels of > 100 IU/L is associated with long-term protection[[136](#_ENREF_136),[137](#_ENREF_137)]. Anti-HBs antibody titers decrease over time and can fall below protective concentrations.

HBV vaccine series should be administered on the standard schedule (3 20-μg doses, administered intramuscularly at 0, 1, and 6 mo) if HBsAg, and anti-HBs antibody, and anti-HBc antibody are all negative. Approximately 90% to 95% of healthy adults have protective anti-HBs titers after standard doses of HBV vaccines[[138](#_ENREF_138),[139](#_ENREF_139)]. However, only 17.5% to 71% of HIV-infected patients could retain protective anti-HBs[[137](#_ENREF_137),[139-148](#_ENREF_139)] (Table 3). In HIV-infected patients, variable immune responses to HBV vaccine has been shown to be associated with dysfunction of CD4 T cells, specific B-cell defects, and hyper-immune activation status and genes within the human leukocyte antigen complex[[149-151](#_ENREF_149)].

In HIV-infected patients, patients with CD4 cell counts ≥ 350 cells/μL had a higher seroconversion rate (anti-HBs ≥ 10 IU/L) than those with CD4 cell counts < 350 cells/μL (39.3% *vs* 26.3%)[[140](#_ENREF_140)]. Failure of anti-HBs seroconversion and lower anti-HBs titers after HBV vaccination in HIV-infected patients have been shown to be associated with detectable plasma HIV RNA, lower CD4 cell counts[[142](#_ENREF_142),[147](#_ENREF_147),[152](#_ENREF_152),[153](#_ENREF_153)], age, HCV coinfection, occult HBV infection, alcohol abuse, and the general health status of the host[[144](#_ENREF_144),[148](#_ENREF_148),[154](#_ENREF_154),[155](#_ENREF_155)]. Favorable response to cART may improve serological response[[137](#_ENREF_137),[156](#_ENREF_156)] (Table 3).

Based on these data, early vaccination is recommended in HIV-infected patients before CD4 cell counts decline. These also strengthen the arguments for universal HBV vaccination of individuals at risk for HIV infection before they become HIV-infected and their immunosuppression worsens. Post-vaccination testing is recommended 1 to 2 mo after administration of the final dose of the primary vaccine series to determine the response to the vaccine. The height of the antibody titers is associated with the durability of effective antibody[[136](#_ENREF_136)].

To improve the response rate and long-term antibodies persistence, numerous studies have tried to use a variety of strategies such as increased doses, intradermal vaccination, and co-administration of immunomodulators. A fundamental strategy is to ensure that patients have optimal adherence to the vaccination schedule. A study conducted in a clinic specializing in the care of HIV-infected adults revealed that 7.5% had evidence or documentation of prior HBV vaccination at screening, and only 49% of those eligible for vaccination completed the standard vaccination schedule[[157](#_ENREF_157)]. Other studies also have reported completion rates ranging from 29% to 62%[[12](#_ENREF_12),[158](#_ENREF_158),[159](#_ENREF_159)].

***Dosing*, *vaccination schedules*, *and administration***

For patients undergoing hemodialysis and for adults with general immune suppression, higher vaccine doses given on a standard schedule (3 40-μg doses administered intramuscularly at 0, 1, 6 mo) are recommended[[160](#_ENREF_160),[161](#_ENREF_161)]. However, appropriate vaccine dosage has not been well defined in HIV-infected patients. In 1 double-blinded, randomized, controlled trial in 210 HIV-infected adults, 94 in the standard-dose group (3 20-μg dose at 0, 1, 6 mo) and 98 in the double-dose group (3 40-μg at 0, 1, 6 mo) completed the study[[140](#_ENREF_140)]. There was no overall benefit in double-dose group (seroconversion rate 47% *vs* 34%, *P* = 0.07), but a statistically significant higher seroconversion rate was found in patients with CD4 cell counts ≥ 350 cells/μL and receiving double doses (64.3% *vs* 39.3%, *P* = 0.008). Double-dose strategy also improved seroconversion compared with standard-dose strategy for patients with HIV viral load < 10000 copies/mL (58.3% *vs* 37.3%, *P* = 0.01). In a small double-blinded, randomized controlled trial comparing a 40-μg dose to a 10-μg dose in 3 administrations[[147](#_ENREF_147)]. An increased dose of HBV vaccine did not increase the response rate in HIV-infected subjects (60.0% *vs* 61.5%, *P* = 0.89). Stratified by CD4 cell count or viral load, CD4 cell count ≥ 200 cells/μL was the only significant factor associated with the response rate and no difference was observed between the 2 different vaccine doses.

For travelers or subjects exposed to HBV, an accelerated vaccination schedule, 3 doses can be given at a 0, 1, and 2 mo, followed by a booster at 12 mo, to achieve rapid protection[[162](#_ENREF_162),[163](#_ENREF_163)]. A randomized study was designed to evaluate the protective efficacy in HIV-infected individuals with an accelerated vaccination schedule (*n* = 407; 3 10-μg doses administered intramuscularly at 0, 1 and 3 wk) in comparison to a standard schedule (*n* = 434; 3 10-μg doses at 0, 4 and 24 wk)[[164](#_ENREF_164)]. The study showed that the compliance with an accelerated schedule was better than that with a standard schedule (91.8% *vs* 82.7%), but the overall response rate was higher in standard schedule arm [50% *vs* 38.7%; difference, 11.3% (95%CI: 4.3-18.3)]. Noninferiority was demonstrated only in patients with CD4 cell counts > 500 cells/μL.

Potsch and colleagues reported a higher response rate (89%) using a modiﬁed HBV vaccination schedules that administered 4 40-μg doses intramuscularly at 0, 4, 8 and 24 wk with 79% achieving antibody titers above 100 IU/L[[145](#_ENREF_145)]. A subsequent study conﬁrmed the results with response rates of 83% and 91% following vaccination with 3 and 4 double doses, respectively[[165](#_ENREF_165)].

An alternative vaccine delivery method, the intradermal route, driven by the fact that the dermis and epidermis of human skin are rich in antigen-presenting cells, could permit vaccine dose sparing, because 20% of the antigen dose has elicited good vaccine responses. It has shown improved immunogenicity in patients with chronic kidney disease[[166](#_ENREF_166)]. However, there are significant operational challenges, such as reformulation, changing from a single- to a multiple-dose presentation, development of intradermal delivery devices and training health workers. An open-label, multicenter, 1:1:1 parallel-group, randomized trial compared standard HBV vaccination schedule (3 20-μg dose administered intramuscularly at 0, 4, 24 wk; *n* = 145), 4 double doses (4 40-μg doses administered intramuscularly at 0, 4, 8 and 24 wk; *n* = 148), or 4 intradermal low-dose (4 4-μg doses administered intradermally at 0, 4, 8 and 24 wk; *n* = 144) in HIV-infected adults with CD4 cell counts ≥ 200 cells/μL[[146](#_ENREF_146)]. At week 28, both the 4 intramuscular double-dose group (82%) and the 4 intradermal low-dose regimen group (77%) showed statistically significantly higher response rates than the standard regimen. Four-dose schedule allowed for the possibility of overcoming age, a negative predictors for response in the standard schedule. However, data on long-term persistence of immunity are yet to be seen, and patients with CD4 cell counts of < 200 cells/μL were not evaluated.

***Vaccine safety***

HBV vaccination appeared to be safe in HIV-infected patients compared with HIV-uninfected persons and has no effect on HIV viral load, progression to AIDS or depletion of CD4 cell counts[[140](#_ENREF_140),[141](#_ENREF_141),[146](#_ENREF_146),[147](#_ENREF_147)] In the study by Launay *et al*[[146](#_ENREF_146)], 1 serious hepatic cytolysis event possibly related to the vaccine was reported in the 4 intramuscular double-dose group. A higher incidence of injection site adverse events was reported in the 4 intramuscular double-dose group compared with the standard group but, these adverse events remained generally mild.

Use of newer adjuvants may also augment hepatitis B vaccine efﬁcacy. Standard hepatitis B vaccines contain aluminum adjuvants. Two new adjuvants in addition to a commercial HBV vaccine have been evaluated in randomized trials in HIV-infected patients[[167-170](#_ENREF_167)]. The granulocyte macrophage colony-stimulating factor (GM-CSF), a cytokine produced primarily by activated T and B lymphocytes that increases neutrophil count, improves APC function, and is involved in the development and perpetuation of cellular immune responses, has been studied as an adjuvant to in HIV-infected individuals[[167-169](#_ENREF_167)]. GM-CSF is safe with expected side effects in HIV-infected subjects when administered as an adjuvant. While 1 study suggested promise for the role to augment immune response[[169](#_ENREF_169)], but no addictive benefits were noted in the 2 other trials[[167](#_ENREF_167),[168](#_ENREF_168)]. CPG 7909, an oligodeoxynucleotide containing immunostimulatory CpG motifs that activates human B and plasmacytoid dendritic cells via Toll-like receptor 9. A randomized, double-blind controlled trial was conducted in HIV-infected adults on effective antiretroviral therapy who underwent HBV vaccination (3 40-μg administered intramuscularly at 0, 1, and 2 mo) with/without 1 mg CPG 7909[[170](#_ENREF_170)]. It showed durable, with significantly more CPG 7909 recipients than control subjects maintaining seroprotective titers for up to 60 mo in vaccine-naive participants and in those who had previously experienced vaccine failure[[170](#_ENREF_170)]. While more studies are warranted to determine optimal vaccination strategies in patients with advanced immunosuppression, the vaccination series should be initiated at first visit regardless of CD4 cell count.

**TREATMENT WITH COMBINATION ANTIRETROVIRAL THERAPY AS PREVENTION FOR HBV INFECTION**

Some health-care practitioner may weigh the risk of vaccination delay and the likelihood of HBV infection in patients when making decisions to postpone vaccination until cART is started and virologic suppression is achieved to improve serologic response to vaccination. A cohort study in Japan examined the prophylaxis effect of against HBV in HIV-infected patients who had not received HBV vaccination and were negative for HBsAg, anti-HBs, and anti-HBc at baseline[[171](#_ENREF_171)]. The incidence rate of HBV infection was lower during LAM- or TDF-containing cART (0.669 incident infections in 100 person-years of follow-up) than during no antiretroviral therapy period (6.726 incident infections in 100 person-years) and other antiretroviral therapy (5.263 incident infections in 100 person-years) (*P* < 0.001). A similar trend was also noted in Taiwan[[172](#_ENREF_172)].

**conclusion**

In this review, we have found in the published data that the prevalence or incidence of HBV infection among the HIV-infected patients is likely to decrease in areas where HBV vaccination programs are implemented and the coverage of cART containing TDF plus LAM or FTC is high. The challenges to prevention for HBV transmission remain to ensure that HIV-monoinfected patients have optimal adherence to protected sex and HBV vaccination schedule, and to identify novel approaches or novel adjuvants to improve vaccination effectiveness. While the experience with management of HBV/HIV-coinfected patients using cART containing TDF plus LAM or FTC is accumulating in the clinical practice, earlier diagnosis of HIV infection and initiation of cART to achieve durable suppression of both HIV and HBV replication in those with coinfection are warranted to ensure the long-term success in prevention for HBV-related chronic complications. With the progress made in liver transplantation over the past decades, early referral for workup for liver transplantation is advised when the HIV/HBV-coinfected patients become symptomatic with liver disease.

**REFERENCES**

1 **Hoffmann CJ**, Thio CL. Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. *Lancet Infect Dis* 2007; **7**: 402-409 [PMID: 17521593 DOI: 10.1016/S1473-3099(07)70135-4]

2 **Kourtis AP**, Bulterys M, Hu DJ, Jamieson DJ. HIV-HBV coinfection--a global challenge. *N Engl J Med* 2012; **366**: 1749-1752 [PMID: 22571198 DOI: 10.1056/NEJMp1201796]

3 **Konopnicki D**, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, Zilmer K, Vella S, Kirk O, Lundgren JD. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. *AIDS* 2005; **19**: 593-601 [PMID: 15802978]

4 **Thio CL**, Seaberg EC, Skolasky R, Phair J, Visscher B, Muñoz A, Thomas DL. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). *Lancet* 2002; **360**: 1921-1926 [PMID: 12493258]

5 **Sheng WH**, Kao JH, Chen PJ, Huang LM, Chang SY, Sun HY, Hung CC, Chen MY, Chang SC. Evolution of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy. *Clin Infect Dis* 2007; **45**: 1221-1229 [PMID: 17918088 DOI: 10.1086/522173]

6 **Chun HM**, Roediger MP, Hullsiek KH, Thio CL, Agan BK, Bradley WP, Peel SA, Jagodzinski LL, Weintrob AC, Ganesan A, Wortmann G, Crum-Cianflone NF, Maguire JD, Landrum ML. Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters. *J Infect Dis* 2012; **205**: 185-193 [PMID: 22147794 DOI: 10.1093/infdis/jir720]

7 **Tsai MS**, Chang SY, Lo YC, Yang CJ, Sun HY, Liu WC, Wu PY, Hung CC. Hepatitis B virus (HBV) coinfection accelerates immunologic progression in patients with primary HIV infection in an area of hyperendemicity for HBV infection. *J Infect Dis* 2013; **208**: 1184-1186 [PMID: 23840045 DOI: 10.1093/infdis/jit299]

8 **Wandeler G**, Gsponer T, Bihl F, Bernasconi E, Cavassini M, Kovari H, Schmid P, Battegay M, Calmy A, Egger M, Furrer H, Rauch A. Hepatitis B virus infection is associated with impaired immunological recovery during antiretroviral therapy in the Swiss HIV cohort study. *J Infect Dis* 2013; **208**: 1454-1458 [PMID: 23901088 DOI: 10.1093/infdis/jit351]

9 **World Health Organization**. Hepatitis B. Available from: URL: http://www.who.int/mediacentre/factsheets/fs204/en/

10 **Thio CL**. Hepatitis B and human immunodeficiency virus coinfection. *Hepatology* 2009; **49**: S138-S145 [PMID: 19399813 DOI: 10.1002/hep.22883]

11 **Denis F**, Adjide CC, Rogez S, Delpeyroux C, Rogez JP, Weinbreck P. [Seroprevalence of HBV, HCV and HDV hepatitis markers in 500 patients infected with the human immunodeficiency virus]. *Pathol Biol (Paris)* 1997; **45**: 701-708 [PMID: 9538467]

12 **Kellerman SE**, Hanson DL, McNaghten AD, Fleming PL. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. *J Infect Dis* 2003; **188**: 571-577 [PMID: 12898445 DOI: 10.1086/377135]

13 **Roca B**, Suarez I, Gonzalez J, Garrido M, de la Fuente B, Teira R, Geijo P, Cosin J, Perez-Cortes S, Galindo MJ, Lozano F, Domingo P, Viciana P, Ribera E, Vergara A, Sánchez T. Hepatitis C virus and human immunodeficiency virus coinfection in Spain. *J Infect* 2003; **47**: 117-124 [PMID: 12860144]

14 **Rosenblum L**, Darrow W, Witte J, Cohen J, French J, Gill PS, Potterat J, Sikes K, Reich R, Hadler S. Sexual practices in the transmission of hepatitis B virus and prevalence of hepatitis delta virus infection in female prostitutes in the United States. *JAMA* 1992; **267**: 2477-2481 [PMID: 1573724]

15 **Osmond DH**, Charlebois E, Sheppard HW, Page K, Winkelstein W, Moss AR, Reingold A. Comparison of risk factors for hepatitis C and hepatitis B virus infection in homosexual men. *J Infect Dis* 1993; **167**: 66-71 [PMID: 8418184]

16 **Piot P**, Goilav C, Kegels E. Hepatitis B: transmission by sexual contact and needle sharing. *Vaccine* 1990; **8** Suppl: S37-40; discussion S41-3 [PMID: 2183516]

17 **Ott JJ**, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. *Vaccine* 2012; **30**: 2212-2219 [PMID: 22273662 DOI: 10.1016/j.vaccine.2011.12.116]

18 **Su WJ**, Liu CC, Liu DP, Chen SF, Huang JJ, Chan TC, Chang MH. Effect of age on the incidence of acute hepatitis B after 25 years of a universal newborn hepatitis B immunization program in Taiwan. *J Infect Dis* 2012; **205**: 757-762 [PMID: 22262790 DOI: 10.1093/infdis/jir852]

19 **McMahon BJ**, Bulkow LR, Singleton RJ, Williams J, Snowball M, Homan C, Parkinson AJ. Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program. *Hepatology* 2011; **54**: 801-807 [PMID: 21618565 DOI: 10.1002/hep.24442]

20 **Chen SM**, Kung CM, Yang WJ, Wang HL. Efficacy of the nationwide hepatitis B infant vaccination program in Taiwan. *J Clin Virol* 2011; **52**: 11-16 [PMID: 21767983 DOI: 10.1016/j.jcv.2011.06.012]

21 **Chang MH**, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, Liang DC, Shau WY, Chen DS. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. *N Engl J Med* 1997; **336**: 1855-1859 [PMID: 9197213 DOI: 10.1056/NEJM199706263362602]

22 **Chiang CJ**, Yang YW, You SL, Lai MS, Chen CJ. Thirty-year outcomes of the national hepatitis B immunization program in Taiwan. *JAMA* 2013; **310**: 974-976 [PMID: 24002285 DOI: 10.1001/jama.2013.276701]

23 **Sun HY**, Ko WC, Tsai JJ, Lee HC, Liu CE, Wong WW, Su SC, Ho MW, Cheng SH, Yang CH, Lin YH, Miao WJ, Sheng WH, Hung CC. Seroprevalence of chronic hepatitis B virus infection among taiwanese human immunodeficiency virus type 1-positive persons in the era of nationwide hepatitis B vaccination. *Am J Gastroenterol* 2009; **104**: 877-884 [PMID: 19259078 DOI: 10.1038/ajg.2008.159]

24 **Sun HY**, Cheng CY, Lee NY, Yang CJ, Liang SH, Tsai MS, Ko WC, Liu WC, Wu PY, Wu CH, Lin HH, Hung CC. Seroprevalence of hepatitis B virus among adults at high risk for HIV transmission two decades after implementation of nationwide hepatitis B virus vaccination program in Taiwan. *PLoS One* 2014; **9**: e90194 [PMID: 24587275 DOI: 10.1371/journal.pone.0090194.]

25 **McMahon BJ**. The influence of hepatitis B virus genotype and subgenotype on the natural history of chronic hepatitis B. *Hepatol Int* 2009; **3**: 334-342 [PMID: 19669359 DOI: 10.1007/s12072-008-9112-z]

26 **Kurbanov F**, Tanaka Y, Mizokami M. Geographical and genetic diversity of the human hepatitis B virus. *Hepatol Res* 2010; **40**: 14-30 [PMID: 20156297 DOI: 10.1111/j.1872-034X.2009.00601.x]

27 **Olinger CM**, Jutavijittum P, Hübschen JM, Yousukh A, Samountry B, Thammavong T, Toriyama K, Muller CP. Possible new hepatitis B virus genotype, southeast Asia. *Emerg Infect Dis* 2008; **14**: 1777-1780 [PMID: 18976569 DOI: 10.3201/eid1411.080437]

28 **Tatematsu K**, Tanaka Y, Kurbanov F, Sugauchi F, Mano S, Maeshiro T, Nakayoshi T, Wakuta M, Miyakawa Y, Mizokami M. A genetic variant of hepatitis B virus divergent from known human and ape genotypes isolated from a Japanese patient and provisionally assigned to new genotype J. *J Virol* 2009; **83**: 10538-10547 [PMID: 19640977 DOI: 10.1128/JVI.00462-09]

29 **Kao JH**, Chen PJ, Lai MY, Chen DS. Genotypes and clinical phenotypes of hepatitis B virus in patients with chronic hepatitis B virus infection. *J Clin Microbiol* 2002; **40**: 1207-1209 [PMID: 11923332]

30 **Sánchez-Tapias JM**, Costa J, Mas A, Bruguera M, Rodés J. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. *Gastroenterology* 2002; **123**: 1848-1856 [PMID: 12454842 DOI: 10.1053/gast.2002.37041]

31 **Yuen MF**, Wong DK, Sablon E, Tse E, Ng IO, Yuan HJ, Siu CW, Sander TJ, Bourne EJ, Hall JG, Condreay LD, Lai CL. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. *Hepatology* 2004; **39**: 1694-1701 [PMID: 15185311 DOI: 10.1002/hep.20240]

32 **Kao JH**, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. *Gastroenterology* 2000; **118**: 554-559 [PMID: 10702206]

33 **Chu CM**, Liaw YF. Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline. *J Hepatol* 2005; **43**: 411-417 [PMID: 16006001 DOI: 10.1016/j.jhep.2005.03.018]

34 **Yang HI**, Yeh SH, Chen PJ, Iloeje UH, Jen CL, Su J, Wang LY, Lu SN, You SL, Chen DS, Liaw YF, Chen CJ. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. *J Natl Cancer Inst* 2008; **100**: 1134-1143 [PMID: 18695135 DOI: 10.1093/jnci/djn243]

35 **Yuen MF**, Tanaka Y, Mizokami M, Yuen JC, Wong DK, Yuan HJ, Sum SM, Chan AO, Wong BC, Lai CL. Role of hepatitis B virus genotypes Ba and C, core promoter and precore mutations on hepatocellular carcinoma: a case control study. *Carcinogenesis* 2004; **25**: 1593-1598 [PMID: 15090469 DOI: 10.1093/carcin/bgh172]

36 **Chan HL**, Hui AY, Wong ML, Tse AM, Hung LC, Wong VW, Sung JJ. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. *Gut* 2004; **53**: 1494-1498 [PMID: 15361502 DOI: 10.1136/gut.2003.033324]

37 **Kao JH**, Chen PJ, Lai MY, Chen DS. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. *Gastroenterology* 2003; **124**: 327-334 [PMID: 12557138 DOI: 10.1053/gast.2003.50053]

38 EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. *J Hepatol* 2012; **57**: 167-185 [PMID: 22436845]

39 **Kao JH**, Wu NH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes and the response to interferon therapy. *J Hepatol* 2000; **33**: 998-1002 [PMID: 11131465]

40 **Wai CT**, Chu CJ, Hussain M, Lok AS. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. *Hepatology* 2002; **36**: 1425-1430 [PMID: 12447868 DOI: 10.1053/jhep.2002.37139]

41 **Erhardt A**, Blondin D, Hauck K, Sagir A, Kohnle T, Heintges T, Häussinger D. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. *Gut* 2005; **54**: 1009-1013 [PMID: 15951551 DOI: 10.1136/gut.2004.060327]

42 **Marcellin P**, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, Jin R, Gurel S, Lu ZM, Wu J, Popescu M, Hadziyannis S. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. *Gastroenterology* 2009; **136**: 2169-2179.e1-4 [PMID: 19303414 DOI: 10.1053/j.gastro.2009.03.006]

43 **Chien RN**, Yeh CT, Tsai SL, Chu CM, Liaw YF. Determinants for sustained HBeAg response to lamivudine therapy. *Hepatology* 2003; **38**: 1267-1273 [PMID: 14578866 DOI: 10.1053/jhep.2003.50458]

44 **Kao JH**, Liu CJ, Chen DS. Hepatitis B viral genotypes and lamivudine resistance. *J Hepatol* 2002; **36**: 303-304 [PMID: 11830346]

45 **Yuen MF**, Wong DK, Sablon E, Yuan HJ, Sum SM, Hui CK, Chan AO, Wang BC, Lai CL. Hepatitis B virus genotypes B and C do not affect the antiviral response to lamivudine. *Antivir Ther* 2003; **8**: 531-534 [PMID: 14760886]

46 **Chan HL**, Wong ML, Hui AY, Chim AM, Tse AM, Hung LC, Chan FK, Sung JJ. Hepatitis B virus genotype has no impact on hepatitis B e antigen seroconversion after lamivudine treatment. *World J Gastroenterol* 2003; **9**: 2695-2697 [PMID: 14669315]

47 **Westland C**, Delaney W, Yang H, Chen SS, Marcellin P, Hadziyannis S, Gish R, Fry J, Brosgart C, Gibbs C, Miller M, Xiong S. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. *Gastroenterology* 2003; **125**: 107-116 [PMID: 12851876]

48 **Hou J**, Yin YK, Xu D, Tan D, Niu J, Zhou X, Wang Y, Zhu L, He Y, Ren H, Wan M, Chen C, Wu S, Chen Y, Xu J, Wang Q, Wei L, Chao G, Constance BF, Harb G, Brown NA, Jia J. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial. *Hepatology* 2008; **47**: 447-454 [PMID: 18080339 DOI: 10.1002/hep.22075]

49 **Dao HY**, Joshi R. Non-A Hepatitis B Genotypes are Associated with More Liver Fibrosis in HIV/HBV Patients. 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2008). San Francisco, USA, 2008

50 **Soriano V**, Mocroft A, Peters L, Rockstroh J, Antunes F, Kirkby N, de Wit S, Monforte Ad, Flisiak R, Lundgren J. Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe. *J Antimicrob Chemother* 2010; **65**: 548-555 [PMID: 20051475 DOI: 10.1093/jac/dkp479]

51 **Thibault V**, Gaudy-Graffin C, Colson P, Gozlan J, Schnepf N, Trimoulet P, Pallier C, Saune K, Branger M, Coste M, Thoraval FR. Epidemiological, virological and clinical characteristics of HBV infection in 223 HIV co-infected patients: a French multi-centre collaborative study. *Virol J* 2013; **10**: 87 [PMID: 23497042 DOI: 10.1186/1743-422X-10-87]

52 **Lacombe K**, Massari V, Girard PM, Serfaty L, Gozlan J, Pialoux G, Mialhes P, Molina JM, Lascoux-Combe C, Wendum D, Carrat F, Zoulim F. Major role of hepatitis B genotypes in liver fibrosis during coinfection with HIV. *AIDS* 2006; **20**: 419-427 [PMID: 16439876 DOI: 10.1097/01.aids.0000200537.86984.0e]

53 **Calin R**, Guiguet M, Desire N, Imbert-Bismut F, Munteanu M, Poynard T, Valantin MA, Stitou H, Katlama C, Thibault V. Role of genotype G hepatitis B virus mixed infection on the progression of hepatic fibrosis in HIV positive patients over 5 years of follow-up. *J Clin Virol* 2013; **58**: 408-414 [PMID: 23958588 DOI: 10.1016/j.jcv.2013.07.018]

54 **Sheng WH**, Hung CC, Chang SY, Liu CJ, Chen MY, Hsieh SM, Kao JH, Chen PJ, Chang SC. Differential clinical and virologic impact of hepatitis B virus genotypes B and C on HIV-coinfected patients receiving lamivudine-containing highly active antiretroviral therapy. *Clin Infect Dis* 2012; **54**: 548-555 [PMID: 22156858 DOI: 10.1093/cid/cir851]

55 **Israël N**, Hazan U, Alcami J, Munier A, Arenzana-Seisdedos F, Bachelerie F, Israël A, Virelizier JL. Tumor necrosis factor stimulates transcription of HIV-1 in human T lymphocytes, independently and synergistically with mitogens. *J Immunol* 1989; **143**: 3956-3960 [PMID: 2574206]

56 **Twu JS**, Chu K, Robinson WS. Hepatitis B virus X gene activates kappa B-like enhancer sequences in the long terminal repeat of human immunodeficiency virus 1. *Proc Natl Acad Sci U S A* 1989; **86**: 5168-5172 [PMID: 2740349]

57 **Gómez-Gonzalo M**, Carretero M, Rullas J, Lara-Pezzi E, Aramburu J, Berkhout B, Alcamí J, López-Cabrera M. The hepatitis B virus X protein induces HIV-1 replication and transcription in synergy with T-cell activation signals: functional roles of NF-kappaB/NF-AT and SP1-binding sites in the HIV-1 long terminal repeat promoter. *J Biol Chem* 2001; **276**: 35435-35443 [PMID: 11457829 DOI: 10.1074/jbc.M103020200]

58 **Eskild A**, Magnus P, Petersen G, Sohlberg C, Jensen F, Kittelsen P, Skaug K. Hepatitis B antibodies in HIV-infected homosexual men are associated with more rapid progression to AIDS. *AIDS* 1992; **6**: 571-574 [PMID: 1388879]

59 **Scharschmidt BF**, Held MJ, Hollander HH, Read AE, Lavine JE, Veereman G, McGuire RF, Thaler MM. Hepatitis B in patients with HIV infection: relationship to AIDS and patient survival. *Ann Intern Med* 1992; **117**: 837-838 [PMID: 1416559]

60 **Sinicco A**, Raiteri R, Sciandra M, Bertone C, Lingua A, Salassa B, Gioannini P. Coinfection and superinfection of hepatitis B virus in patients infected with human immunodeficiency virus: no evidence of faster progression to AIDS. *Scand J Infect Dis* 1997; **29**: 111-115 [PMID: 9181644]

61 **Bodsworth NJ**, Cooper DA, Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. *J Infect Dis* 1991; **163**: 1138-1140 [PMID: 2019762]

62 **Hadler SC**, Judson FN, O'Malley PM, Altman NL, Penley K, Buchbinder S, Schable CA, Coleman PJ, Ostrow DN, Francis DP. Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. *J Infect Dis* 1991; **163**: 454-459 [PMID: 1825315]

63 **Oshitani H**, Kasolo FC, Mpabalwani M, Mizuta K, Luo NP, Suzuki H, Numazaki Y. Prevalence of hepatitis B antigens in human immunodeficiency virus type 1 seropositive and seronegative pregnant women in Zambia. *Trans R Soc Trop Med Hyg* 1996; **90**: 235-236 [PMID: 8758060]

64 **Rouet F**, Chaix ML, Inwoley A, Msellati P, Viho I, Combe P, Leroy V, Dabis F, Rouzioux C. HBV and HCV prevalence and viraemia in HIV-positive and HIV-negative pregnant women in Abidjan, Côte d'Ivoire: the ANRS 1236 study. *J Med Virol* 2004; **74**: 34-40 [PMID: 15258966 DOI: 10.1002/jmv.20143]

65 **Colin JF**, Cazals-Hatem D, Loriot MA, Martinot-Peignoux M, Pham BN, Auperin A, Degott C, Benhamou JP, Erlinger S, Valla D, Marcellin P. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. *Hepatology* 1999; **29**: 1306-1310 [PMID: 10094979 DOI: 10.1002/hep.510290447]

66 **Sheng WH**, Chen MY, Hsieh SM, Hsiao CF, Wang JT, Hung CC, Chang SC. Impact of chronic hepatitis B virus (HBV) infection on outcomes of patients infected with HIV in an area where HBV infection is hyperendemic. *Clin Infect Dis* 2004; **38**: 1471-1477 [PMID: 15156487 DOI: 10.1086/420744]

67 **Sheng WH**, Hung CC, Kao JH, Chang SY, Chen MY, Hsieh SM, Chen PJ, Chang SC. Impact of hepatitis D virus infection on the long-term outcomes of patients with hepatitis B virus and HIV coinfection in the era of highly active antiretroviral therapy: a matched cohort study. *Clin Infect Dis* 2007; **44**: 988-995 [PMID: 17342655 DOI: 10.1086/511867]

68 **Hung CC**, Wu SM, Lin PH, Sheng WH, Yang ZY, Sun HY, Tsai MS, Lee KY, Su YC, Liu WC, Chang SY. Increasing Incidence of Recent Hepatitis D Virus Infection in HIV-Infected Patients in an Area Hyperendemic for Hepatitis B Virus Infection. *Clin Infect Dis* 2014; Epub ahead of print [PMID: 24599769]

69 **Lok AS**, McMahon BJ. Chronic hepatitis B: update 2009. *Hepatology* 2009; **50**: 661-662 [PMID: 19714720 DOI: 10.1002/Hep.23190]

70 **Marcellin P**, Boyer N, Colin JF, Martinot-Peignoux M, Lefort V, Matheron S, Erlinger S, Benhamou JP. Recombinant alpha interferon for chronic hepatitis B in anti-HIV positive patients receiving zidovudine. *Gut* 1993; **34**: S106 [PMID: 8314471]

71 **Johnson RM**, Ristig MB, Overton ET, Lisker-Melman M, Cummings OW, Aberg JA. Safety and tolerability of sequential pegylated IFN-alpha2a and tenofovir for hepatitis B infection in HIV(+) individuals. *HIV Clin Trials* 2007; **8**: 173-181 [PMID: 17621464 DOI: 10.1310/hct0803-173]

72 **Benhamou Y**, Bochet M, Thibault V, Calvez V, Fievet MH, Vig P, Gibbs CS, Brosgart C, Fry J, Namini H, Katlama C, Poynard T. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. *Lancet* 2001; **358**: 718-723 [PMID: 11551579]

73 **Matthews GV**, Seaberg EC, Avihingsanon A, Bowden S, Dore GJ, Lewin SR, Sasadeusz J, Revill PA, Littlejohn M, Hoy JF, Finlayson R, Ruxrungtham K, Saulynas M, Locarnini S, Thio CL. Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus. *Clin Infect Dis* 2013; **56**: e87-e94 [PMID: 23315316 DOI: 10.1093/cid/cit002]

74 **Soriano V**, Tuma P, Vispo E, Labarga P, Fernández JV, Medrano J, Barreiro P. Hepatitis B in HIV patients: what is the current treatment and what are the challenges? *J HIV Ther* 2009; **14**: 13-18 [PMID: 19731560]

75 **Negredo E**, Garrabou G, Puig J, Lòpez S, Morén C, Bellido R, Ayen R, Cardellach F, Miró O, Clotet B. Partial immunological and mitochondrial recovery after reducing didanosine doses in patients on didanosine and tenofovir-based regimens. *Antivir Ther* 2008; **13**: 231-240 [PMID: 18505174]

76 **Taburet AM**, Piketty C, Chazallon C, Vincent I, Gérard L, Calvez V, Clavel F, Aboulker JP, Girard PM. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. *Antimicrob Agents Chemother* 2004; **48**: 2091-2096 [PMID: 15155205 DOI: 10.1128/AAC.48.6.2091-2096.2004]

77 **van Maarseveen NM**, Wensing AM, de Jong D, Beilhartz GL, Obikhod A, Tao S, Pingen M, Arends JE, Hoepelman AI, Schinazi RF, Götte M, Nijhuis M. Telbivudine exerts no antiviral activity against HIV-1 in vitro and in humans. *Antivir Ther* 2011; **16**: 1123-1130 [PMID: 22024528 DOI: 10.3851/IMP1912]

78 **Peters MG**, Andersen J, Lynch P, Liu T, Alston-Smith B, Brosgart CL, Jacobson JM, Johnson VA, Pollard RB, Rooney JF, Sherman KE, Swindells S, Polsky B. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. *Hepatology* 2006; **44**: 1110-1116 [PMID: 17058225 DOI: 10.1002/hep.21388]

79 **Ratcliffe L**, Beadsworth MB, Pennell A, Phillips M, Vilar FJ. Managing hepatitis B/HIV co-infected: adding entecavir to truvada (tenofovir disoproxil/emtricitabine) experienced patients. *AIDS* 2011; **25**: 1051-1056 [PMID: 21346511 DOI: 10.1097/QAD.0b013e328345ef5e]

80 **Committee AIS**. A randomized placebo-controlled trial of adefovir dipivoxil in advanced HIV infection: the ADHOC trial. *HIV Med* 2002; **3**: 229-238 [PMID: 12444940]

81 **Milazzo L**, Caramma I, Lai A, Violin M, De Maddalena C, Cesari M, Galli M, Balotta C. Telbivudine in the treatment of chronic hepatitis B: experience in HIV type-1-infected patients naive for antiretroviral therapy. *Antivir Ther* 2009; **14**: 869-872 [PMID: 19812451 DOI: 10.3851/1303]

82 (OARAC) OoARAC. DHHS Guidelines for the Use of Anti-retroviral Agents in HIV-1-infected Adults and Adolescents. AIDS info website 2013. Available from: URL: http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf

83 EACS European AIDS Clinical Society. EACS Guidelines Version 7.0. 2013 Available from: URL: http://www.eacsociety.org/Portals/0/Guidelines\_Online\_131014.pdf

84 **Wilkins E**, Nelson M, Agarwal K, Awoyemi D, Barnes E, Bhagani S, Brook G, Brown A, Castelino S, Cooke G, Fisher M, Geretti AM, James R, Kulasegaram R, Leen C, Mutimer D, Orkin C, Page E, Palfreeman A, Papineni P, Rodger A, Tong CY. British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013. *HIV Med* 2013; **14 Suppl 4**: 1-71 [PMID: 24581304 DOI: 10.1111/hiv.12106]

85 **Dore GJ**, Cooper DA, Barrett C, Goh LE, Thakrar B, Atkins M. Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. *J Infect Dis* 1999; **180**: 607-613 [PMID: 10438346 DOI: 10.1086/314942]

86 **Wolters LM**, Niesters HG, Hansen BE, van der Ende ME, Kroon FP, Richter C, Brinkman K, Meenhorst PL, de Man RA. Development of hepatitis B virus resistance for lamivudine in chronic hepatitis B patients co-infected with the human immunodeficiency virus in a Dutch cohort. *J Clin Virol* 2002; **24**: 173-181 [PMID: 11856618]

87 **Hoff J**, Bani-Sadr F, Gassin M, Raffi F. Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens. *Clin Infect Dis* 2001; **32**: 963-969 [PMID: 11247719 DOI: 10.1086/319368]

88 **Benhamou Y**, Bochet M, Thibault V, Di Martino V, Caumes E, Bricaire F, Opolon P, Katlama C, Poynard T. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. *Hepatology* 1999; **30**: 1302-1306 [PMID: 10534354 DOI: 10.1002/hep.510300525]

89 **Chang TT**, Lai CL, Chien RN, Guan R, Lim SG, Lee CM, Ng KY, Nicholls GJ, Dent JC, Leung NW. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. *J Gastroenterol Hepatol* 2004; **19**: 1276-1282 [PMID: 15482535 DOI: 10.1111/j.1440-1746.2004.03428.x]

90 **Matthews GV**, Bartholomeusz A, Locarnini S, Ayres A, Sasaduesz J, Seaberg E, Cooper DA, Lewin S, Dore GJ, Thio CL. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. *AIDS* 2006; **20**: 863-870 [PMID: 16549970 DOI: 10.1097/01.aids.0000218550.85081.59]

91 **Cooksley WG**, Piratvisuth T, Lee SD, Mahachai V, Chao YC, Tanwandee T, Chutaputti A, Chang WY, Zahm FE, Pluck N. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. *J Viral Hepat* 2003; **10**: 298-305 [PMID: 12823597]

92 **Lau GK**, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. *N Engl J Med* 2005; **352**: 2682-2695 [PMID: 15987917 DOI: 10.1056/NEJMoa043470]

93 **Neumann A**, Polis M, Rozenberg L, Jackson J, Reitano K, McLaughlin M, Koratich C, Dewar R, Masur H, Haagmans B, Kottilil S. Differential antiviral effect of PEG-interferon-alpha-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients. *AIDS* 2007; **21**: 1855-1865 [PMID: 17721093 DOI: 10.1097/QAD.0b013e32825eaba7]

94 **Liu MQ**, Zhou DJ, Wang X, Zhou W, Ye L, Li JL, Wang YZ, Ho WZ. IFN-λ3 inhibits HIV infection of macrophages through the JAK-STAT pathway. *PLoS One* 2012; **7**: e35902 [PMID: 22558263 DOI: 10.1371/journal.pone.0035902]

95 **Mauss S**, Valenti W, DePamphilis J, Duff F, Cupelli L, Passe S, Solsky J, Torriani FJ, Dieterich D, Larrey D. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. *AIDS* 2004; **18**: F21-F25 [PMID: 15316334]

96 **Liaw YF**. Results of lamivudine trials in Asia. *J Hepatol* 2003; **39 Suppl 1**: S111-S115 [PMID: 14708688]

97 **Borroto-Esoda K**, Parkin N, Miller MD. A comparison of the phenotypic susceptibility profiles of emtricitabine and lamivudine. *Antivir Chem Chemother* 2007; **18**: 297-300 [PMID: 18046962]

98 **Yang H**, Qi X, Sabogal A, Miller M, Xiong S, Delaney WE. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. *Antivir Ther* 2005; **10**: 625-633 [PMID: 16152756]

99 **Gish RG**, Trinh H, Leung N, Chan FK, Fried MW, Wright TL, Wang C, Anderson J, Mondou E, Snow A, Sorbel J, Rousseau F, Corey L. Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study. *J Hepatol* 2005; **43**: 60-66 [PMID: 15922478 DOI: 10.1016/j.jhep.2005.02.017]

100 **Nüesch R**, Ananworanich J, Srasuebkul P, Chetchotisakd P, Prasithsirikul W, Klinbuayam W, Mahanontharit A, Jupimai T, Ruxrungtham K, Hirschel B. Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection. *AIDS* 2008; **22**: 152-154 [PMID: 18090405 DOI: 10.1097/QAD.0b013e3282f303bf]

101 **Bartholomeusz A**, Locarnini S. Hepatitis B virus mutations associated with antiviral therapy. *J Med Virol* 2006; **78 Suppl 1**: S52-S55 [PMID: 16622878 DOI: 10.1002/jmv.20608]

102 **Thio CL**, Locarnini S. Treatment of HIV/HBV coinfection: clinical and virologic issues. *AIDS Rev* 2007; **9**: 40-53 [PMID: 17474312]

103 **Benhamou Y**, Thibault V, Vig P, Calvez V, Marcelin AG, Fievet MH, Currie G, Chang CG, Biao L, Xiong S, Brosgart C, Poynard T. Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. *J Hepatol* 2006; **44**: 62-67 [PMID: 16274835 DOI: 10.1016/j.jhep.2005.08.020]

104 **Marcellin P**, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jeffers L, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. *N Engl J Med* 2003; **348**: 808-816 [PMID: 12606735 DOI: 10.1056/NEJMoa020681]

105 **Hadziyannis SJ**, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Ma J, Brosgart CL, Borroto-Esoda K, Arterburn S, Chuck SL. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. *Gastroenterology* 2006; **131**: 1743-1751 [PMID: 17087951 DOI: 10.1053/j.gastro.2006.09.020]

106 **Lampertico P**, Viganò M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. *Gastroenterology* 2007; **133**: 1445-1451 [PMID: 17983801 DOI: 10.1053/j.gastro.2007.08.079]

107 **Yatsuji H**, Suzuki F, Sezaki H, Akuta N, Suzuki Y, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Watahiki S, Iwasaki S, Kobayashi M, Kumada H. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up. *J Hepatol* 2008; **48**: 923-931 [PMID: 18433925 DOI: 10.1016/j.jhep.2008.02.019]

108 **Dore GJ**, Cooper DA, Pozniak AL, DeJesus E, Zhong L, Miller MD, Lu B, Cheng AK. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. *J Infect Dis* 2004; **189**: 1185-1192 [PMID: 15031786 DOI: 10.1086/380398]

109 **Nelson M**, Portsmouth S, Stebbing J, Atkins M, Barr A, Matthews G, Pillay D, Fisher M, Bower M, Gazzard B. An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals. *AIDS* 2003; **17**: F7-10 [PMID: 12478090 DOI: 10.1097/01.aids.0000042959.95433.c1]

110 **Kosi L**, Reiberger T, Payer BA, Grabmeier-Pfistershammer K, Strassl R, Rieger A, Peck-Radosavljevic M. Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients. *J Viral Hepat* 2012; **19**: 801-810 [PMID: 23043387 DOI: 10.1111/j.1365-2893.2012.01601.x]

111 **Price H**, Dunn D, Pillay D, Bani-Sadr F, de Vries-Sluijs T, Jain MK, Kuzushita N, Mauss S, Núñez M, Nüesch R, Peters M, Reiberger T, Stephan C, Tan L, Gilson R. Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis. *PLoS One* 2013; **8**: e68152 [PMID: 23874527 DOI: 10.1371/journal.pone.0068152]

112 **Cooper RD**, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. *Clin Infect Dis* 2010; **51**: 496-505 [PMID: 20673002 DOI: 10.1086/655681]

113 **Pessôa MG**, Gazzard B, Huang AK, Brandão-Mello CE, Cassetti I, Mendes-Corrêa MC, Soriano V, Phiri P, Hall A, Brett-Smith H. Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy. *AIDS* 2008; **22**: 1779-1787 [PMID: 18753861 DOI: 10.1097/QAD.0b013e32830b3ab5]

114 **McMahon MA**, Jilek BL, Brennan TP, Shen L, Zhou Y, Wind-Rotolo M, Xing S, Bhat S, Hale B, Hegarty R, Chong CR, Liu JO, Siliciano RF, Thio CL. The HBV drug entecavir - effects on HIV-1 replication and resistance. *N Engl J Med* 2007; **356**: 2614-2621 [PMID: 17582071 DOI: 10.1056/NEJMoa067710]

115 **Tenney DJ**, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L, Plym M, Pokornowski K, Yu CF, Angus P, Ayres A, Bartholomeusz A, Sievert W, Thompson G, Warner N, Locarnini S, Colonno RJ. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. *Antimicrob Agents Chemother* 2004; **48**: 3498-3507 [PMID: 15328117 DOI: 10.1128/AAC.48.9.3498-3507.2004]

116 **Lai CL**, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, Chen Y, Heathcote EJ, Rasenack J, Bzowej N, Naoumov NV, Di Bisceglie AM, Zeuzem S, Moon YM, Goodman Z, Chao G, Constance BF, Brown NA. Telbivudine versus lamivudine in patients with chronic hepatitis B. *N Engl J Med* 2007; **357**: 2576-2588 [PMID: 18094378 DOI: 10.1056/NEJMoa066422]

117 **Liaw YF**, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, Heathcote EJ, Manns M, Bzowej N, Niu J, Han SH, Hwang SG, Cakaloglu Y, Tong MJ, Papatheodoridis G, Chen Y, Brown NA, Albanis E, Galil K, Naoumov NV. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. *Gastroenterology* 2009; **136**: 486-495 [PMID: 19027013 DOI: 10.1053/j.gastro.2008.10.026]

118 **Chen CJ**, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. *JAMA* 2006; **295**: 65-73 [PMID: 16391218 DOI: 10.1001/jama.295.1.65]

119 **Papatheodoridis GV**, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. *J Hepatol* 2010; **53**: 348-356 [PMID: 20483498 DOI: 10.1016/j.jhep.2010.02.035]

# 120 [Hosaka T](http://www.ncbi.nlm.nih.gov/pubmed?term=Hosaka%20T%5BAuthor%5D&cauthor=true&cauthor_uid=23213040), [Suzuki F](http://www.ncbi.nlm.nih.gov/pubmed?term=Suzuki%20F%5BAuthor%5D&cauthor=true&cauthor_uid=23213040), [Kobayashi M](http://www.ncbi.nlm.nih.gov/pubmed?term=Kobayashi%20M%5BAuthor%5D&cauthor=true&cauthor_uid=23213040), [Seko Y](http://www.ncbi.nlm.nih.gov/pubmed?term=Seko%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=23213040), [Kawamura Y](http://www.ncbi.nlm.nih.gov/pubmed?term=Kawamura%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=23213040), [Sezaki H](http://www.ncbi.nlm.nih.gov/pubmed?term=Sezaki%20H%5BAuthor%5D&cauthor=true&cauthor_uid=23213040), [Akuta N](http://www.ncbi.nlm.nih.gov/pubmed?term=Akuta%20N%5BAuthor%5D&cauthor=true&cauthor_uid=23213040), [Suzuki Y](http://www.ncbi.nlm.nih.gov/pubmed?term=Suzuki%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=23213040), [Saitoh S](http://www.ncbi.nlm.nih.gov/pubmed?term=Saitoh%20S%5BAuthor%5D&cauthor=true&cauthor_uid=23213040), [Arase Y](http://www.ncbi.nlm.nih.gov/pubmed?term=Arase%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=23213040), [Ikeda K](http://www.ncbi.nlm.nih.gov/pubmed?term=Ikeda%20K%5BAuthor%5D&cauthor=true&cauthor_uid=23213040), [Kobayashi M](http://www.ncbi.nlm.nih.gov/pubmed?term=Kobayashi%20M%5BAuthor%5D&cauthor=true&cauthor_uid=23213040), [Kumada H](http://www.ncbi.nlm.nih.gov/pubmed?term=Kumada%20H%5BAuthor%5D&cauthor=true&cauthor_uid=23213040). Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virusinfection.

*Hepatology* 2013; **58**: 98-107 [PMID: 24122922 DOI: 10.1002/hep.26774]

121 **Núñez M**, Pérez-Olmeda M, Díaz B, Ríos P, González-Lahoz J, Soriano V. Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine. *AIDS* 2002; **16**: 2352-2354 [PMID: 12441815]

122 **Schmutz G**, Nelson M, Lutz T, Sheldon J, Bruno R, von Boemmel F, Hoffmann C, Rockstroh J, Stoehr A, Wolf E, Soriano V, Berger F, Berg T, Carlebach A, Schwarze-Zander C, Schürmann D, Jaeger H, Mauss S. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. *AIDS* 2006; **20**: 1951-1954 [PMID: 16988516 DOI: 10.1097/01.aids.0000247116.89455.5d]

123 **Antiretroviral Therapy Cohort Collaboration**. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. *Lancet* 2008; **372**: 293-299 [PMID: 18657708 DOI: 10.1016/S0140-6736(08)61113-7]

124 **Tuma P**, Medrano J, Resino S, Vispo E, Madejón A, Sánchez-Piedra C, Rivas P, Labarga P, Martín-Carbonero L, Barreiro P, Soriano V. Incidence of liver cirrhosis in HIV-infected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapy. *Antivir Ther* 2010; **15**: 881-886 [PMID: 20834100 DOI: 10.3851/Imp1630]

125 **Martín-Carbonero L**, Teixeira T, Poveda E, Plaza Z, Vispo E, González-Lahoz J, Soriano V. Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues. *AIDS* 2011; **25**: 73-79 [PMID: 21076274 DOI: 10.1097/Qad.0b013e328340fde2]

126 **Clifford GM**, Rickenbach M, Polesel J, Dal Maso L, Steffen I, Ledergerber B, Rauch A, Probst-Hensch NM, Bouchardy C, Levi F, Franceschi S. Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. *AIDS* 2008; **22**: 2135-2141 [PMID: 18832877 DOI: 10.1097/Qad.0b013e32831103ad]

127 **Deeken JF**, Pantanowitz L, Dezube BJ. Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook. *Curr Opin Oncol* 2009; **21**: 445-454 [PMID: 19606034 DOI: 10.1097/Cco.0b013e32832f3e04]

128 **Chelis L**, Ntinos N, Souftas V, Deftereos S, Xenidis N, Chamalidou E, Maltezos E, Kakolyris S. Complete response after sorafenib therapy for hepatocellular carcinoma in an HIV-HBV co infected patient: Possible synergy with HAART ? A case report. *Med Oncol* 2011; **28 Suppl 1**: S165-S168 [PMID: 20809183 DOI: 10.1007/s12032-010-9669-y]

129 **Perboni G**, Costa P, Fibbia GC, Morandini B, Scalzini A, Tagliani A, Cengarle R, Aitini E. Sorafenib therapy for hepatocellular carcinoma in an HIV-HCV coinfected patient: a case report. *Oncologist* 2010; **15**: 142-145 [PMID: 20142333 DOI: 10.1634/theoncologist.2010-0010]

130 **Ozenne V**, Gervais A, Peytavin G, Castelnau C, Valla DC, Degos F. Suspected interaction between sorafenib and HAART in an HIV-1 infected patient: a case report. *Hepatogastroenterology* 2011; **58**: 161-162 [PMID: 21510306]

131 **Coffin CS**, Stock PG, Dove LM, Berg CL, Nissen NN, Curry MP, Ragni M, Regenstein FG, Sherman KE, Roland ME, Terrault NA. Virologic and clinical outcomes of hepatitis B virus infection in HIV-HBV coinfected transplant recipients. *Am J Transplant* 2010; **10**: 1268-1275 [PMID: 20346065 DOI: 10.1111/j.1600-6143.2010.03070.x]

132 **Tateo M**, Roque-Afonso AM, Antonini TM, Medja F, Lombes A, Jardel C, Teicher E, Sebagh M, Roche B, Castaing D, Samuel D, Duclos-Vallee JC. Long-term follow-up of liver transplanted HIV/hepatitis B virus coinfected patients: perfect control of hepatitis B virus replication and absence of mitochondrial toxicity. *AIDS* 2009; **23**: 1069-1076 [PMID: 19417577 DOI: 10.1097/QAD.0b013e32832c2a37]

133 Solid Organ Transplant in HIV: Multi-Site Study. When to Start the Transplant Referral Process. Available from: URL: http://spitfire.emmes.com/study/htr/

134 **Alter MJ**. Epidemiology of viral hepatitis and HIV co-infection. *J Hepatol* 2006; **44**: S6-S9 [PMID: 16352363 DOI: 10.1016/j.jhep.2005.11.004]

135 **Lee WM**. Hepatitis B virus infection. *N Engl J Med* 1997; **337**: 1733-1745 [PMID: 9392700 DOI: 10.1056/NEJM199712113372406]

136 **Lopes VB**, Hassing RJ, de Vries-Sluijs TE, El Barzouhi A, Hansen BE, Schutten M, de Man RA, van der Ende ME. Long-term response rates of successful hepatitis B vaccination in HIV-infected patients. *Vaccine* 2013; **31**: 1040-1044 [PMID: 23273969 DOI: 10.1016/j.vaccine.2012.12.047]

137 **Paitoonpong L**, Suankratay C. Immunological response to hepatitis B vaccination in patients with AIDS and virological response to highly active antiretroviral therapy. *Scand J Infect Dis* 2008; **40**: 54-58 [PMID: 17852939 DOI: 10.1080/00365540701522975]

138 **Lemon SM**, Thomas DL. Vaccines to prevent viral hepatitis. *N Engl J Med* 1997; **336**: 196-204 [PMID: 8988900 DOI: 10.1056/NEJM199701163360307]

139 **Irungu E**, Mugo N, Ngure K, Njuguna R, Celum C, Farquhar C, Dhanireddy S, Baeten JM. Immune response to hepatitis B virus vaccination among HIV-1 infected and uninfected adults in Kenya. *J Infect Dis* 2013; **207**: 402-410 [PMID: 23175769 DOI: 10.1093/infdis/jis695]

140 **Fonseca MO**, Pang LW, de Paula Cavalheiro N, Barone AA, Heloisa Lopes M. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. *Vaccine* 2005; **23**: 2902-2908 [PMID: 15780739 DOI: 10.1016/j.vaccine.2004.11.057]

141 **Rey D**, Krantz V, Partisani M, Schmitt MP, Meyer P, Libbrecht E, Wendling MJ, Vetter D, Nicolle M, Kempf-Durepaire G, Lang JM. Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. *Vaccine* 2000; **18**: 1161-1165 [PMID: 10649616]

142 **Overton ET**, Sungkanuparph S, Powderly WG, Seyfried W, Groger RK, Aberg JA. Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. *Clin Infect Dis* 2005; **41**: 1045-1048 [PMID: 16142673 DOI: 10.1086/433180]

143 **Tedaldi EM**, Baker RK, Moorman AC, Wood KC, Fuhrer J, McCabe RE, Holmberg SD. Hepatitis A and B vaccination practices for ambulatory patients infected with HIV. *Clin Infect Dis* 2004; **38**: 1478-1484 [PMID: 15156488 DOI: 10.1086/420740]

144 **Kim HN**, Harrington RD, Van Rompaey SE, Kitahata MM. Independent clinical predictors of impaired response to hepatitis B vaccination in HIV-infected persons. *Int J STD AIDS* 2008; **19**: 600-604 [PMID: 18725550 DOI: 10.1258/ijsa.2007.007197]

145 **Potsch DV**, Oliveira ML, Ginuíno C, Miguel JC, Oliveira SA, Silva EF, Moreira RB, Cruz GV, Oliveira AL, Camacho LA, Barroso PF. High rates of serological response to a modified hepatitis B vaccination schedule in HIV-infected adults subjects. *Vaccine* 2010; **28**: 1447-1450 [PMID: 19995540 DOI: 10.1016/j.vaccine.2009.11.066]

146 **Launay O**, van der Vliet D, Rosenberg AR, Michel ML, Piroth L, Rey D, Colin de Verdière N, Slama L, Martin K, Lortholary O, Carrat F. Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial. *JAMA* 2011; **305**: 1432-1440 [PMID: 21486976 DOI: 10.1001/jama.2011.351]

147 **Cornejo-Juárez P**, Volkow-Fernández P, Escobedo-López K, Vilar-Compte D, Ruiz-Palacios G, Soto-Ramírez LE. Randomized controlled trial of Hepatitis B virus vaccine in HIV-1-infected patients comparing two different doses. *AIDS Res Ther* 2006; **3**: 9 [PMID: 16600028 DOI: 10.1186/1742-6405-3-9]

148 **Ungulkraiwit P**, Jongjirawisan Y, Atamasirikul K, Sungkanuparph S. Factors for predicting successful immune response to hepatitis B vaccination in HIV-1 infected patients. *Southeast Asian J Trop Med Public Health* 2007; **38**: 680-685 [PMID: 17883006]

149 **Chedid MG**, Deulofeut H, Yunis DE, Lara-Marquez ML, Salazar M, Deulofeut R, Awdeh Z, Alper CA, Yunis EJ. Defect in Th1-like cells of nonresponders to hepatitis B vaccine. *Hum Immunol* 1997; **58**: 42-51 [PMID: 9438208]

150 **Shokrgozar MA**, Shokri F. Enumeration of hepatitis B surface antigen-specific B lymphocytes in responder and non-responder normal individuals vaccinated with recombinant hepatitis B surface antigen. *Immunology* 2001; **104**: 75-79 [PMID: 11576223]

151 **Wang C**, Tang J, Song W, Lobashevsky E, Wilson CM, Kaslow RA. HLA and cytokine gene polymorphisms are independently associated with responses to hepatitis B vaccination. *Hepatology* 2004; **39**: 978-988 [PMID: 15057902 DOI: 10.1002/hep.20142]

152 **Bruguera M**, Cremades M, Salinas R, Costa J, Grau M, Sans J. Impaired response to recombinant hepatitis B vaccine in HIV-infected persons. *J Clin Gastroenterol* 1992; **14**: 27-30 [PMID: 1532609]

153 **Veiga AP**, Casseb J, Duarte AJ. Humoral response to hepatitis B vaccination and its relationship with T CD45RA+ (naïve) and CD45RO+ (memory) subsets in HIV-1-infected subjects. *Vaccine* 2006; **24**: 7124-7128 [PMID: 16884833 DOI: 10.1016/j.vaccine.2006.06.079]

154 **Gandhi RT**, Wurcel A, McGovern B, Lee H, Shopis J, Corcoran CP, Toner S, Giachetti C, Dockter J, Sax PE, Ukomadu C. Low prevalence of ongoing hepatitis B viremia in HIV-positive individuals with isolated antibody to hepatitis B core antigen. *J Acquir Immune Defic Syndr* 2003; **34**: 439-441 [PMID: 14615664]

155 **Shire NJ**, Rouster SD, Rajicic N, Sherman KE. Occult hepatitis B in HIV-infected patients. *J Acquir Immune Defic Syndr* 2004; **36**: 869-875 [PMID: 15213572]

156 **Moir S**, Fauci AS. Pathogenic mechanisms of B-lymphocyte dysfunction in HIV disease. *J Allergy Clin Immunol* 2008; **122**: 12-9; quiz 20-1 [PMID: 18547629 DOI: 10.1016/j.jaci.2008.04.034]

157 **Bailey CL**, Smith V, Sands M. Hepatitis B vaccine: a seven-year study of adherence to the immunization guidelines and efficacy in HIV-1-positive adults. *Int J Infect Dis* 2008; **12**: e77-e83 [PMID: 18723381 DOI: 10.1016/j.ijid.2008.05.1226]

158 **Landrum ML**, Huppler Hullsiek K, Ganesan A, Weintrob AC, Crum-Cianflone NF, Barthel RV, Peel S, Agan BK. Hepatitis B vaccine responses in a large U.S. military cohort of HIV-infected individuals: another benefit of HAART in those with preserved CD4 count. *Vaccine* 2009; **27**: 4731-4738 [PMID: 19540026 DOI: 10.1016/j.vaccine.2009.04.016]

159 **Winnock M**, Neau D, Castera L, Viot J, Lacoste D, Pellegrin JL, Dupon M, Jutand MA, Colombani F, Dabis F. Hepatitis B vaccination in HIV-infected patients: a survey of physicians and patients participating in the Aquitaine cohort. *Gastroenterol Clin Biol* 2006; **30**: 189-195 [PMID: 16565650]

160 . Recommendations for preventing transmission of infections among chronic hemodialysis patients. *MMWR Recomm Rep* 2001; **50**: 1-43 [PMID: 11349873]

161 **Poland GA**, Jacobson RM. Clinical practice: prevention of hepatitis B with the hepatitis B vaccine. *N Engl J Med* 2004; **351**: 2832-2838 [PMID: 15625334 DOI: 10.1056/NEJMcp041507]

162 **Connor BA**, Patron DJ. Use of an accelerated immunization schedule for combined hepatitis A and B protection in the corporate traveler. *J Occup Environ Med* 2008; **50**: 945-950 [PMID: 18695453 DOI: 10.1097/JOM.0b013e3181808081]

163 **Marchou B**, Excler JL, Bourderioux C, Salaun J, Picot N, Yvonnet B, Cerisier JE, Salomon H, Auvergnat JC. A 3-week hepatitis B vaccination schedule provides rapid and persistent protective immunity: a multicenter, randomized trial comparing accelerated and classic vaccination schedules. *J Infect Dis* 1995; **172**: 258-260 [PMID: 7797926]

164 **de Vries-Sluijs TE**, Hansen BE, van Doornum GJ, Kauffmann RH, Leyten EM, Mudrikova T, Brinkman K, den Hollander JG, Kroon FP, Janssen HL, van der Ende ME, de Man RA. A randomized controlled study of accelerated versus standard hepatitis B vaccination in HIV-positive patients. *J Infect Dis* 2011; **203**: 984-991 [PMID: 21266513 DOI: 10.1093/infdis/jiq137]

165 **Potsch DV**, Camacho LA, Tuboi S, Villar LM, Miguel JC, Ginuíno C, Silva EF, Mendonça RM, Moreira RB, Barroso PF. Vaccination against hepatitis B with 4-double doses increases response rates and antibodies titers in HIV-infected adults. *Vaccine* 2012; **30**: 5973-5977 [PMID: 22828589 DOI: 10.1016/j.vaccine.2012.07.028]

166 **Fabrizi F**, Dixit V, Magnini M, Elli A, Martin P. Meta-analysis: intradermal vs. intramuscular vaccination against hepatitis B virus in patients with chronic kidney disease. *Aliment Pharmacol Ther* 2006; **24**: 497-506 [PMID: 16886915 DOI: 10.1111/j.1365-2036.2006.03002.x]

167 **Overton ET**, Kang M, Peters MG, Umbleja T, Alston-Smith BL, Bastow B, Demarco-Shaw D, Koziel MJ, Mong-Kryspin L, Sprenger HL, Yu JY, Aberg JA. Immune response to hepatitis B vaccine in HIV-infected subjects using granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant: ACTG study 5220. *Vaccine* 2010; **28**: 5597-5604 [PMID: 20600512 DOI: 10.1016/j.vaccine.2010.06.030]

168 **Overton ET**, Sungkanuparph S, Klebert M, Royal M, Demarco-Shaw D, Powderly WG, Aberg JA. GM-CSF Fails to Improve Immune Responses to Booster Hepatitis B Vaccination in HIV-Infected Individuals. *Open Virol J* 2011; **5**: 109-113 [PMID: 22043256 DOI: 10.2174/1874357901105010109]

169 **Sasaki Md**, Foccacia R, de Messias-Reason IJ. Efficacy of granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant for hepatitis B virus in patients with HIV infection. *Vaccine* 2003; **21**: 4545-4549 [PMID: 14575766]

170 **Cooper CL**, Angel JB, Seguin I, Davis HL, Cameron DW. CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years. *Clin Infect Dis* 2008; **46**: 1310-1314 [PMID: 18444872 DOI: 10.1086/533467]

171 **Gatanaga H**, Hayashida T, Tanuma J, Oka S. Prophylactic effect of antiretroviral therapy on hepatitis B virus infection. *Clin Infect Dis* 2013; **56**: 1812-1819 [PMID: 23487374 DOI: 10.1093/cid/cit145]

172 **Sheng WH**, Chuang YC, Sun HY, Tsai MS, Chang SY, Hung CC, Chang SC. Prophylactic effect of lamivudine-based antiretroviral therapy on incident hepatitis B virus infection among HIV-infected patients. *Clin Infect Dis* 2013; **57**: 1504-1506 [PMID: 23926178 DOI: 10.1093/cid/cit511]

**P-Reviewers:** Farzin R, Manesis EK, Mudawi HMY, Said ZNA, Yang YF **S-Editor:** Gou SX  **L-Editor: E-Editor:**

**Figure 1 Seroprevalence of hepatitis B virus infection in human immunodeficiency virus-infected patients according to birth year in Taiwan.** The seroprevalence declined significantly from 20.3% in those who were born before in 1984 (*n* = 3034) when neonatal hepatitis B virus (HBV) vaccination provided to newborns whose mothers tested positive for HBV surface antigen (HBsAg) to 3.7% in those who were born after 1986 (*n* = 507) when universal neonatal vaccination and catch-up vaccination were implemented[[23](#_ENREF_23),[24](#_ENREF_24)] .

**Table 1 Characteristics of antiviral drugs for chronic hepatitis B in human immunodeficiency virus-infected patients**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Characteristics** | Interferon alfa--2b1 | **Pegylated interferon alfa--2a1** | **Lamivudine** | **Emtricitabine** | **Adefovir** | **Entecavir** | **Telbivudine** | **Tenofovirdisoproxil fumarate** |
| Antiviral effect | Immune modulation | Immune modulation | Interfere HBV DNA synthesis | Interfere HBV DNA synthesis | Interfere HBV DNA synthesis | Interfere HBV DNA synthesis | Interfere HBV DNA synthesis | Interfere HBV DNA synthesis |
| HIV-1activity | No | No | Yes | Yes | No, at low dose2 | Yes | No7 | Yes |
| Dosage and administration | 10 million IU SC or IM 3 times a week | 180 mg SC once a week | Oral 300 mg/d | Oral 200 mg/d | Oral 10 mg/d | Oral 0.5 mg/d5 | Oral 600 mg/d. | Oral 300 mg/d |
| Defined treatment duration  | 48 wk | 48 wk | Indefinite | Indefinite | Indefinite | Indefinite | Indefinite | Indefinite |
| Undetectable HBV DNA  | - | - | 40%-84% at 1 yr | 53% at 2 yr | -\*\* | -\*\*\* | - | Up to 91% at 5 yr |
| HBeAg seroconversion | 0%-20% | 0%-20% | 22%-35% at 1 yr | 14% at 48 wk | 9% at 144 wk | - | - | 50% of TDF use; 57% of TDF plus FTC use at 5 yr |
| Tolerability | Poor | Poor | Excellent | Excellent | Good | Excellent | Good | Good |
| Major adverse events | Leukopenia, depression | Leukopenia, depression | - | - | Nephrotoxicity (3%) | - | - | Nephrotoxicity (1%-3%) |
| Viral resistance barrier | No | No | Low (50% at 2 yr and 90% at 4 yr) | Intermediate (18% at 2 yr) | High | High | - | High |
| HBV resistancemutations | No | No | M204I/VL180MA181T/VV173L | M204I/VL180MA181T/V | N236TA181T/V | M204I/V4L180MT184I/A/G/LS202I/GI169T | M204IA181T/V | A194T3A181T/VN236T |
| Cross-resistance to LAM | No | No | - | Yes | No | No | Yes | No |
| Interaction with other antiretrovirals | No | No | No | No | No | No | Zidovudine; stavudine6 | Didanosine; atazanavir6 |

1HBeAg positive subjects with CD4 cell counts of > 350 cells/μl and aminotransferase levels elevated to at least twice the upper limit of normal probably might get the greatest benefit from IFN-alfa therapy[[70](#_ENREF_70),[71](#_ENREF_71)]; 2While ADV (20 mg/d) does have minimal HIV-1 activity, development of HIV-1 resistance mutations has not been demonstrated at low dose adefovir (10 mg/d)[[72](#_ENREF_72),[80](#_ENREF_80)]; 3TDF mutations have not been clearly associated with decreased anti-HBV efficacy[[73](#_ENREF_73)]; 4Presence of several mutations is necessary to decrease efficacy for ETV at a dose of 1 mg/d; 51 mg per day for LAM-resistant HBV infection; 6LdT is a thymidine analogue that might interact with zidovudine or stavudine[[74](#_ENREF_74)]. TDF can interact with [didanosine](http://en.wikipedia.org/wiki/Didanosine) by increasing didanosine's concentration and impairing immunologic response[[75](#_ENREF_75)]. It also decreases the concentration of [atazanavir](http://en.wikipedia.org/wiki/Atazanavir) sulfate[[76](#_ENREF_76)]; 7LdT showed a potent anti-HBV activity in HIV-1-positive, hepatitis B e antigen-positive patients with high HBV viraemia in a case report. However, a transient reduction of HIV-1 RNA between 2 and 3 log10 copies/mL after 24 wk of telbivudine therapy for in 2 out of 3 patients although no genotypic resistance mutations to anti-HIV-1 was found[[81](#_ENREF_81)]. In another study reported 2 patients received LdT treatment[[77](#_ENREF_77)], there was no significant decline of HIV-1 RNA load nor in selection of genotypic or phenotypic resistance in HIV-1 RT. In vitro virologic analyses demonstrated that LdT had no activity against wild type HIV and drug-resistant variants; 8In a prospective randomized, double-blind, placebo-controlled trial of daily 10 mg of ADV *vs* 300 mg of TDF in subjects with HBV and HIV coinfection on stable ART, with serum HBV DNA >100000 copies/mL, and plasma HIV-1 RNA < 10000 copies/mL. The mean time-weighted average change in serum HBV DNA from baseline to week 48 was -4.44 log10 copies/mL for TDF and -3.21 log10 copies/mL for ADV[[78](#_ENREF_78)]; 9In a small cohort of 13 patients with positive HBeAg and detectable HBV DNA who had received > 6 mo of TDF/FTC therapy, add-on ETV to TDF/FTC-experienced patients achieved undetectable HBV DNA load in 4 (30%) and normal ALT levels in 8 (62%)[[79](#_ENREF_79)]. ADV: Adefovir dipivoxil; ETV: Entecavir; FTC: Emtricitabine; HBV: Hepatitis B virus; HBe: HBV envelope antigen; IM: Intramuscularly; LAM: Lamivudine; LdT: Telbivudine; SC: Subcutaneously; TDF: Tenofovir disoproxil fumarate.

**Table 2 Comparisons regarding the use of anti-hepatitis B virus agents in human immunodeficiency virus-infected patients among the different guidelines**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Agents for HBV treatment only** | **Agents for HBV/HIV treatment** | **Timing of cART initiation** | **Comments** |
| DHHS 2013[[82](#_ENREF_82)] | ADV, ETV, or LdT | TDF can safely be used:TDF/LAM-containing cART or TDF/FTC-containing cARTTDF cannot safely be used:ETV plus LAM-cART, orETV plus LAM-cART | HBV: NAHIV: prioritized; regardless of CD4 count | CART may attenuate liver disease progression by preserving or restoring immune function and reducing HIV-related immune activation and inflammation |
| EACS 2013[[83](#_ENREF_83)] | ADV and LdT | LAM-naïvecART including TDF/LAM or FTCLAM-experiencedAdd or substitute 1 NRTI with TDF as part of cARTHBV treatment indicatedEarly ART including TDF/FTC or LAMPEF-IFN (if genotype A, high ALT, low HBV DNA) | HBV: HBV DNA > 2000 IU/mL; significant liver fibrosis (F2-F4) even when HBV-DNA is below 2000 IU/mL and liver enzymes are not elevated.HIV: CD4 < 500 cells/μL or symptomatic HIV, cirrhosis, or HBV treatment indicated | The optimal treatment duration for nucleos(*t*)ide analogues with anti-HBV activity has not yet been determined and experts recommend life-long therapy if anti-HBV nucleos(*t*)ides are given as part of ARTIn persons with HBV genotype A, high ALT and low HBV DNA, PEG-IFN might be used for a total length of 48 wk. The addition of an NRTI-based anti-HBV regimen has not been proved to increase PFG-IFN efficacy.In persons with liver cirrhosis, stopping effective anti-HBV treatment is not recommended in order to avoid liver decompensation due to flares of liver enzymes.Anti-HBV therapy may be stopped cautiously in HBeAg-positive persons who have achieved HBe seroconversion for at least 6 mo or after confirmed HBs seroconversion in those who are HBeAg-positive.The addition of ETV to TDF in persons with low persistent HB -replication has not statistically proved to be efficient and should therefore be avoided.Caution is warranted to switch from a TDF-based regimen to drugs with a lower genetic barrier, *e.g.*, FTC or LAM, in particular in LAM-pretreated cirrhotic persons as viral breakthrough due to archived YMDD mutations is likely to occur. |
| BHIVA 2013[[84](#_ENREF_84)] | NA | CD4 count >500 cells/μL:TDF/FTC-cARTUnwilling or unable to receive TDF/FTC: ADV or 48 wk of PEG-IFN plus cARTCD4 count < 500 cells/μL:Wild-type HBV: TDF/FTC-cART or TDF/LAM-cARTLAM/FTC-resistant HBV or HIV: TDF as the sole anti-HBV active agentTDF is contraindicated: ETV plus cART | HBV: HBV DNA > 2000 IU/mL; more than minimal fibrosis on liver biopsy (Metavir > F2 or Ishak > S2) or indicative of > F2 by TE (FibroScan > 9.0 kPa) regardless of HBV DNAHIV: CD4 < 500 cells/μL or patients requiring HBV therapy | At least 2 baseline HBV DNA measurements 3 to 6 mo apart to guide initiation of therapy6-mo HBV DNA measurements for routine monitoring of therapyAn ALT level below the upper limit of normal (30 IU/L for men; 19 IU/L for women) should not be used to exclude fibrosis or as a reason to defer HBV therapy |

ADV: Adefovir dipivoxil; ALT: Alanine aminotransferase; cART: Combination antiretroviral therapy; ETV: Entacavir; FTC: Emtricitabine; HBV: Hepatitis B virus; LAM: Lamivudine; LdT: Telbivudine; NA: Not available; PEF-IFN: Pegylated interferon; TDF: Tenofovir disoproxil fumarate; TE: Transient elastography.

**Table 3 Hepatitis B vaccine in adults with human immunodeficiency virus: Standard and alternative strategies**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Reference** | **Year** | **Study design** | ***n*** | **Dose** | **Schedules/ administration** | **Age, median, yr** | **CART** | **HIV-1 VL, RNA copies/mL < 10000**  | **CD4, median, cells/μL** | **Response rate** | **Predictors** |
| **Standard-dose vaccination** |
| Rey *et al*[[141](#_ENREF_141)] | 2000 | Prospective | 20 | 3 × 20 μg | 0, 1, 2 mo, IM | 30.5 | 85% | NA | 470 | 55% | CD4 > 500 cells/μL |
| Tedaldi *et al*[[143](#_ENREF_143)] | 2004 | Retrospective, cross-sectional | 198 | 52.5% ≥ 3 × 20 μg | NA | 41 | 70.7% | > 75% | 406 | 37.2% | Higher CD4;HIV-1 VL < level of detection |
| Overton *et al*[[142](#_ENREF_142)] | 2005 | Retrospective | 194 | 3 × 10 μg (97%-99%) | 0, 1 to 3, 6-9 mo, IM | 34.1 | 82.0% | 38.1% ( < 400) | 290 | 17.5% | HIV-1 VL < level of detection |
| Ungulkraiwit *et al*[[148](#_ENREF_148)] | 2007 | Prospective | 65 | 3 × 20 μg | 0, 1, 6 mo, IM | 39 | 88% | > 75% | 345 | 46% | Higher CD4;young age |
| Paitoonpong *et al*[[137](#_ENREF_137)] | 2008 | Prospective | 28 | 3 × 20 μg | 0, 1, 6 mo, IM | 35 | 100% | 100% (< 50) | 324 | 71.4% | Higher CD4;use of efavirenz |
| Kim *et al*[[144](#_ENREF_144)] | 2008 | Retrospective | 97 | 3 × 20 μg | 0, 1, 6 mo, IM | 39 | 31% | 24% (< 400) | 325 | 44% | Nadir CD4>200 cells/μL;young age ( < 40 yr);HIV-1 VL < level of detection |
| Irungu *et al*[[139](#_ENREF_139)] | 2013 | Prospective | 293 | 3 × 20 μg | 0, 1 to 3, 6 mo, IM | 31 | HIV-1 uninfected | 85.7% | CD4 > 500 cells/μL; female |
| 310 | 0% | 65.7% | 557 | 64.2% |
| **Alternative strategies** |
| Fonseca *et al*[[140](#_ENREF_140)] | 2005 | RCT | 94 | 3 × 20 μg | 0, 1, 6 mo, IM | 37 | 85.1% | 80.9% | ≥ 350, 59.6 | 34% | CD4 > 350 cells/μL;HIV-1 VL < 10000 copies/mL |
| 98 | 3 × 40 μg | 87.8% | 75.5 | ≥ 350, 57.1 | 47% (*P* = 0.07) |
| Cornejo-Juárez *et al*[[147](#_ENREF_147)] | 2006 | RCT | 39 | 3 × 10 μg | 0, 1, 6 mo, IM | 35.6 | 56.4% | ≤ 20000, 56.6 | ≥ 200, 48.8 | 61.5% | CD4 ≥ 200 cells/μL |
| 40 | 3 × 40 μg | 34.1 | 72.5% | ≤ 20000, 55.6 | ≥ 350, 47.5 | 60% (*P* = 0.89) |
| Potsch *et al*[[145](#_ENREF_145)] | 2010 | Prospective | 47 | 3 × 40 μg | 0, 1, 2, 6 mo, IM | 36 | 79% | < 80, 70 | 402 | 89% | HIV-1 VL < 80 copies/mL |
| Launay *et al*[[146](#_ENREF_146)] | 2011 | RCT | 145 | 3 × 20 μg | 0, 1, 6 mo, IM | 43 | 86% | < 50, 79 | 516 | 65 (95%CI: 56-72) | Young age;four-dose |
| 148 | 4 × 40 μg | 0, 1, 2, 6 mo, IM | 42 | 80% | < 50, 77 | 509 | 82% (95%CI: 77-88) |
| 144 | 4 × 4 μg | 0, 1, 2, 6 mo, ID | 43 | 86% | < 50, 78 | 482 | 77 (95%CI: 56-72) |

ID: Intradermal injections; IM Intramuscular injections; RCT: Randomized clinical trial; VL: Viral load; cART: Combination antiretroviral therapy.